
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.fd58ea5df9e9.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.5d5264180f2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.0d368674b6c6.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.6539a0a78536cfdc1fa6.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs3.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-bloodcancer.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.8317a1b015d1b931f12d.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>MEK inhibitors as a chemotherapeutic intervention in multiple myeloma - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD13AA984BCEE500004AF0455C374D.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="1.0.0.post1+5886d65" />

<meta name="ncbi_domain" content="bloodcancer" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC3615214/" />


    

    

    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Blood Cancer Journal" /><meta name="citation_title" content="MEK inhibitors as a chemotherapeutic intervention in multiple myeloma" /><meta name="citation_author" content="C Chang-Yew Leow" /><meta name="citation_author_institution" content="Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia" /><meta name="citation_author" content="S Gerondakis" /><meta name="citation_author_institution" content="Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia" /><meta name="citation_author_institution" content="Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia" /><meta name="citation_author" content="A Spencer" /><meta name="citation_author_institution" content="Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia" /><meta name="citation_author_institution" content="Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia" /><meta name="citation_publication_date" content="2013/03" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="3" /><meta name="citation_firstpage" content="e105" /><meta name="citation_doi" content="10.1038/bcj.2013.1" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3615214/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC3615214/" /><meta name="citation_pmid" content="23524590" /><meta name="DC.Title" content="MEK inhibitors as a chemotherapeutic intervention in multiple myeloma" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="C Chang-Yew Leow" /><meta name="DC.Contributor" content="S Gerondakis" /><meta name="DC.Contributor" content="A Spencer" /><meta name="DC.Date" content="2013 Mar" /><meta name="DC.Identifier" content="10.1038/bcj.2013.1" /><meta name="DC.Language" content="en" /><meta property="og:title" content="MEK inhibitors as a chemotherapeutic intervention in multiple myeloma" /><meta property="og:type" content="article" /><meta property="og:description" content="The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png?_=0" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" />


</head>
<body >

   
    
    


    <section class="pmc-notice usa-banner site-banner">
          <div role="banner" class="usa-grid usa-banner-header usa-banner-inner pmc-notice__banner pmc-notice--hidden" aria-hidden="true"  data-key="pmc-banner-legacy">
                  <div>

                      <p>The new PMC design is here!
                          <a href="https://www.ncbi.nlm.nih.gov/pmc/about/userguide/#quickguide" data-ga-category="Banner link" data-ga-action="click" data-ga-label="from_article_to_launch_post">Learn more</a>
                          about navigating our updated article layout. The
                          <a href="https://pmclegacy.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/" data-ga-category="Banner link" data-ga-action="click" data-ga-label="visit_legacy_from_live">PMC legacy view</a>
                          will also be available for a limited time.
                      </p>
                  </div>
                  <button tabindex="0" class="close" ><i class="fa fa-window-close"></i></button>
          </div>

    </section>

    
        <section class="pmc-alerts">
    
    
</section>
    

    
        <button
          class="back-to-top back-to-top--base"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form action="/pmc/" class="usa-search " autocomplete="off">
      <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
      <span class="clearable">
        <input
          required="required"
          autocomplete-url="/pmc/autocomplete/pmc/"
          placeholder="Search PMC Full-Text Archive"
          id="pmc-search" type="search" name="term"/>
          <i class="clear-btn" ></i>
      </span>
      <button type="submit">
        <span class="usa-search-submit-text">Search</span>
      </button>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/1694/">Blood Cancer J</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/221395/">v.3(3); 2013 Mar</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC3615214
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                


    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pubreader-link other_item"><a href="/pmc/articles/PMC3615214/?report=reader" class="sidefm-pmclink">PubReader</a></li>
<li class="pdf-link other_item"><a href="/pmc/articles/PMC3615214/pdf/bcj20131a.pdf" class="int-view">PDF (340K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/?format=citation&id=3615214" data-citation-style="nlm"
                        data-download-format-method="get"
                        data-download-format-link="https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/?format=medline&id=3615214&download=true"><span class="button-label">Cite</span></button>
            </li>
            <li>
                
                    




    <div class="favorites-button-container"
         id="pmc-favorites-button"
         data-toggle-favorites-enabled="false"
         data-add-to-favorites-url-hash="#add-to-favorites"
         data-in-favorites="false"
         data-toggle-url="https://www.ncbi.nlm.nih.gov/pmc/toggle-favorites-collection/PMC3615214/"
         data-collections-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"
         data-remove-from-favorites-text="Remove from Favorites collection"
         data-add-to-favorites-text="Add to Favorites collection"
         data-display-title-attr="Favorites">
        
            <a href="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A//www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/%23add-to-favorites"
               class="usa-button favorites-button favorites-button-empty favorites-button-link"
               id="pmc-favorites-button-link"
               
               aria-label="Add to Favorites collection"
               >
                Favorites
            </a>
        
    </div>


                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3615214%2F&amp;text=MEK%20inhibitors%20as%20a%20chemotherapeutic%20intervention%20in%20multiple%20myeloma" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3615214%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    
        <section>
            <h6>RESOURCES</h6>
            <ul class="pmc-sidebar__pubmed_links">
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&amp;from_uid=23524590">Similar articles in PubMed</a></li>
            </ul>
        </section>
    

            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/1694/">Blood Cancer J</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/221395/">v.3(3); 2013 Mar</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC3615214
                </li>
            
    </ul>
 

        </section>
        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-bcj.gif" alt="Logo of bloodcancer" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.nature.com/bcj" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
             
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Blood Cancer J.</span> 2013 Mar; 3(3): e105. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2013 Mar 22. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1038%2Fbcj.2013.1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1038/bcj.2013.1</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3615214</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/23524590">23524590</a></div></div></div><h1 class="content-title">MEK inhibitors as a chemotherapeutic intervention in multiple myeloma</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chang-Yew%20Leow%20C%5BAuthor%5D" class="affpopup" co-rid="_co_idm140618066025536" co-class="co-affbox">C Chang-Yew Leow</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gerondakis%20S%5BAuthor%5D" class="affpopup" co-rid="_co_idm140618061365440" co-class="co-affbox">S Gerondakis</a>,<sup>1,</sup><sup>2</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Spencer%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm140618066023168" co-class="co-affbox">A Spencer</a><sup>1,</sup><sup>2,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140618066025536"><h3 class="no_margin">C Chang-Yew Leow</h3><p><sup>1</sup>Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chang-Yew%20Leow%20C%5BAuthor%5D">C Chang-Yew Leow</a></div></div><div id="_co_idm140618061365440"><h3 class="no_margin">S Gerondakis</h3><p><sup>1</sup>Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia</p><p><sup>2</sup>Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gerondakis%20S%5BAuthor%5D">S Gerondakis</a></div></div><div id="_co_idm140618066023168"><h3 class="no_margin">A Spencer</h3><p><sup>1</sup>Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia</p><p><sup>2</sup>Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Spencer%20A%5BAuthor%5D">A Spencer</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140618094433344_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140618094433344_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140618094433344_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140618094433344_ai" style="display:none"><div class="fm-affl" id="aff1"><sup>1</sup>Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, The Alfred Hospital, Melbourne, Victoria, Australia</div><div class="fm-affl" id="aff2"><sup>2</sup>Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia</div><div id="caf1"><sup>*</sup>Myeloma Research Group, Australian Centre for Blood Diseases and Division of Blood Cancers, Level 1 AMREP, The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3000, Australia. E-mail: <a href="mailto:dev@null" data-email="ua.ten.ecapsten@recnepsa" class="oemail">ua.ten.ecapsten@recnepsa</a></div></div><div class="fm-article-notes hide half_rhythm" id="idm140618094433344_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2012 Nov 1; Accepted 2013 Jan 9.</div></div><div class="permissions half_rhythm hide" id="idm140618094433344_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2013 Macmillan Publishers Limited</div><div class="license half_rhythm">This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm" role="complementary" aria-label="Related or updated information about this article."><div>This article has been <a href="/pmc/articles/PMC3615214/citedby/">cited by</a> other articles in PMC.</div></div></div><div class="sec"></div><div id="abstract-1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-1title">Abstract</h2><!--article-meta--><div><p id="__p1" class="p p-first-last">The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">multiple myeloma, MEK inhibitors, Ras/MAPK, MEK</span></div></div><div id="__sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec1title">Introduction</h2><p id="__p2" class="p p-first">Mitogen-activated protein kinases (MAPKs) are a family of ubiquitously expressed serine/threonine kinases that transmit diverse cell surface signals throughout the cell. MAPK pathways consist of a three-tiered signalling module activated via a phosphorylation cascade. The most proximal kinase in these pathways, the MAPK kinase kinase (MAPKKK or MAP3k), engaged by extracellular signals, phosphorylates a dual specificity MAPK kinase (MAPKK or MAP2K), which in turn phosphorylates and actives the distil effector MAPK. Mammalian MAPK pathways are represented by the Extracellular Signal Regulated Kinase (ERK), c-Jun N-terminal kinase, p38, ERK 5, ERK 3/4 and ERK 7/8 pathways.<sup><a href="#bib1" rid="bib1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973078">1</a></sup></p><p id="__p3">The Ras/MAPK pathway is the best characterised of the mammalian MAPK signal transduction networks, consisting of the Ras proteins, a family of small G-coupled molecules, the Raf kinases (MAP3K), the MAP2K kinases (MEK1 and MEK2) and the pathway distil kinases ERK1 and ERK2. The Ras/MAPK network is frequently deregulated in malignancy and contributes to many of the hallmarks of oncogenesis, including abnormal cellular proliferation, impaired apoptosis, enhanced angiogenesis, metastasis and the development of drug resistance.<sup><a href="#bib2" rid="bib2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973082">2</a></sup> MEK lies at a critical juncture within the Ras/MAPK pathway, having a limited number of direct upstream MAP3K activators and ERK1/2 as its only known cellular targets, thereby making it an attractive target for cancer therapy. Several MEK inhibitors have been developed and investigated in preclinical and clinical models. Results from these studies have been promising and suggest that MEK inhibitors, whether alone or in combination with other anticancer therapies, may have a significant role to play in the future management of malignancy.</p><p id="__p4" class="p">Current management strategies for multiple myeloma (MM) involve conventional chemotherapeutics and novel anti-MM agents (thalidomide, lenalidomide and bortezomib), with or without subsequent autologous stem cell transplantation.<sup><a href="#bib3" rid="bib3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973091">3</a></sup> Although these anticancer therapies are typically effective initially, MM remains a fatal and largely incurable disease. This is due to the high frequency of relapse and the eventual development of drug resistance. Accumulative genetic changes within malignant plasma cells, together with MM interplay with the bone marrow microenvironment (BMME), potentiate disease progression by promoting the deregulation of multiple signal transduction networks, one of which is the Ras/MAPK pathway.<sup><a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973093">4</a>, <a href="#bib5" rid="bib5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973110">5</a></sup> This suggests that MM patients may benefit from the abrogation of this kinase network through the administration of a MEK inhibitor. Here, we discuss the Ras/MAPK pathway, its involvement in MM and the role of MEK inhibitors in the future management of the disease.</p><div id="__sec2" class="sec"><h3 id="__sec2title">Overview of the Ras/Raf/MEK/ERK pathway</h3><p id="__p5" class="p p-first">Members of the Ras protein subfamily (H-, K- and N-Ras) function as molecular switches in cellular signal transduction. Diverse growth factor, mitogen and cytokine engagement of cognate receptors leads to the recruitment of the GDP/GTP exchange factors, growth-factor-receptor bound protein 2 (Grp2) and Sons of Sevenless (SOS) to the plasma membrane where Ras resides. The grp2/SOS complex then promotes inactive Ras to exchange GDP with GTP and enters an activated state.<sup><a href="#bib6" rid="bib6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973136">6</a></sup> Activated Ras then recruits Raf to the cell membrane, where it is activated by phosphorylation. This process is antagonised by GTPase-activating proteins, which promote GTP hydrolysis and the formation of inactive Ras-GDP complexes.<sup><a href="#bib7" rid="bib7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973139">7</a></sup> Approximately 30&#x00025; of malignancies contain activating mutations in a Ras proto-oncogene, with pancreatic (90&#x00025;), colon (50&#x00025;) and thyroid (50&#x00025;) carcinomas demonstrating the highest prevalence. Mutations typically affect K-Ras and N-Ras, but rarely H-Ras, and occur in a mutually exclusive manner.<sup><a href="#bib8" rid="bib8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973138">8</a></sup></p><p id="__p6">The Raf family of serine/threonine kinases (A-, B- and c-Raf (Raf-1)) lie at the apex of the MEK/ERK pathway. All three Raf isoforms share similar structural characteristics. However, they differ in their ability to phosphorylate and activate MEK, with B-Raf demonstrating higher basal kinase activity compared with Raf-1 and A-Raf.<sup><a href="#bib9" rid="bib9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973100">9</a>, <a href="#bib10" rid="bib10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973068">10</a></sup> Activating B-Raf mutations have been described in 66&#x00025; of melanomas and to a lesser degree in other solid tumours.<sup><a href="#bib11" rid="bib11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973047">11</a></sup> The clinical relevance of this association is reinforced by the exquisite sensitivity of these B-Raf mutated tumours to MEK inhibition.<sup><a href="#bib12" rid="bib12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973135">12</a></sup> Despite a high prevalence of activating B-Raf mutations in melanoma and solid tumours, these mutations are infrequent in MM.<sup><a href="#bib13" rid="bib13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973126">13</a></sup> This suggests that molecules other than B-Raf or alternative kinase pathways may have a crucial role in MM tumourigenesis.</p><p id="__p7">MEK is a unique dual specificity kinase that phosphorylates both serine/threonine and tyrosine residues.<sup><a href="#bib14" rid="bib14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973051">14</a></sup> MEK consists of two isoforms, MEK1 and MEK2, which in turn phosphorylate ERK1 and ERK2.<sup><a href="#bib15" rid="bib15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973097">15</a></sup> Activated ERK1/2 control a diverse range of cellular processes through their many substrates (&#x0003e;160) that are located in cellular membranes, the cytoplasm and nucleus. Many of these are transcription factors that are important in cellular proliferation, differentiation, survival, angiogenesis and migration.<sup><a href="#bib16" rid="bib16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973050">16</a></sup></p><p id="__p8" class="p p-last">Physiological activation of the Ras/MAPK pathway is also influenced by multiple mechanisms. Inhibitory molecules, such as Sprouty proteins (SPRY) and MAPK phosphatases (MKP or DUSPs), engage the pathway at different points to negatively regulate signalling.<sup><a href="#bib17" rid="bib17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973104">17</a>, <a href="#bib18" rid="bib18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973094">18</a></sup> Activated ERK induces the expression of these inhibitory factors. For example, certain DUSPs, induced by ERK-regulated transcription factors, dephosphorylate ERK.<sup><a href="#bib19" rid="bib19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973103">19</a></sup> Downstream signalling from B-Raf, Raf-1 and MEK1 may also be diminished following ERK-mediated phosphorylation.<sup><a href="#bib20" rid="bib20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973137">20</a>, <a href="#bib21" rid="bib21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973075">21</a></sup> These various mechanisms fine tune the activity of the Ras/MAPK cascade through the creation of a negative-feedback loop. As will be discussed later, this mode of regulation has implications for inhibitors targeting the pathway.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">The Ras/MAPK pathway and MM</h3><p id="__p9" class="p p-first">The genetic changes associated with MM are complex and heterogeneous. Increasing evidence suggests that the disease evolves through a multistep transformation process, involving the gain or loss of whole chromosomes, nonrandom chromosomal translocations involving the IgH locus and point mutations.<sup><a href="#bib4" rid="bib4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973061">4</a></sup> These aberrations, which influence the clinical and pathological features of MM are manifest in variable disease progression and therapeutic outcomes.</p><p id="__p10">Several of these molecular alterations lead to deregulated activation of the Ras/MAPK pathway. The t(4;14) translocation that juxtaposes the fibroblast growth factor receptor 3 gene and a strong IgH enhancer, resulting in fibroblast growth factor receptor 3 overexpression, stimulates the Ras/MAPK pathway, an outcome typically associated with abnormal cellular proliferation and apoptosis.<sup><a href="#bib22" rid="bib22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973087">22</a></sup> Activating Ras mutations, which have a reported incidence varying between 32&#x02013;50&#x00025; in MM, are also thought to deregulate this pathway.<sup><a href="#bib23" rid="bib23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973119">23</a>, <a href="#bib24" rid="bib24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973090">24</a>, <a href="#bib25" rid="bib25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973108">25</a></sup> K-Ras and N- Ras are the most frequently mutated, with oncogenic H-Ras being a rare phenomenon.<sup><a href="#bib25" rid="bib25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973084">25</a></sup></p><p id="__p11">While certain genetic lesions common to MM (for example, t(14;16), t(4;14) and hyperdiploidy) are also present in the asymptomatic precursor to MM, monoclonal gammopathy of unknown significance,<sup><a href="#bib26" rid="bib26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973064">26</a></sup> Ras mutations occur almost exclusively in MM. This indicates that Ras mutations are likely to contribute to the transition of the disease from a premalignant state.<sup><a href="#bib27" rid="bib27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_380891259">27</a></sup> In the case of the t(4:14) lesion that can activate the Ras/MAPK pathway, this raises the interesting possibility that deregulation of the Ras/MAPK pathway in monoclonal gammopathy of unknown significance precedes constitutive MAPK activation associated with Ras mutations. Patients with MM harbouring oncogenic K-Ras often have a worse clinical outcomes compared with those with N-Ras mutations or wild-type Ras <sup><a href="#bib24" rid="bib24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973086">24</a></sup> This link is exemplified by Ras mutations being associated with the evolution of MM from an intermedullary disease to a more advanced extramedullary phenotype.<sup><a href="#bib28" rid="bib28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973060">28</a></sup> These observations suggest that aberrant MEK/ERK signalling has an important role in MM disease progression and prognosis.</p><p id="__p12">Malignant plasma cell and BMME interactions are thought to contribute to disease progression through the induction of various cytokines and growth factors, a number of which mediate their effects through the Ras/MAPK cascade.<sup><a href="#bib5" rid="bib5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973057">5</a>, <a href="#bib29" rid="bib29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973055">29</a>, <a href="#bib30" rid="bib30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973132">30</a></sup> In addition to a number of these cytokines being able to activate MEK/ERK via the classical Ras/Raf link, another MAP3K, Tpl2 (Cot, MAP3K8), a known oncogene, has emerged as being important in the cytokine-induced activation of ERK in various cell types, in particular hemopoietic cells.<sup><a href="#bib31" rid="bib31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973113">31</a></sup> The observation that the tumour necrosis factor receptor superfamily cytokines (tumour necrosis factor-&#x003b1;, BAFF), CD40 and RANK ligands, all of which have been implicate in MM, activate MEK/ERK via Tpl2 raises the likelihood that the MEK/ERK arm of this MAPK pathway can be activated through different MAP3K.<sup><a href="#bib32" rid="bib32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973096">32</a></sup> With aberrant MEK/ERK signalling thought to be important in regulating the growth, survival, migration and drug resistance of MM, it will be interesting to determine if specific MAP3Ks differentially control these particular features of the disease.</p><p id="__p13" class="p p-last">Interactions between Bcl-2-like prosurvival and BH3-only pro-apoptotic family members play an integral role in controlling the balance between cell survival and death though the intrinsic apoptosis pathway. Aberrant expression of these apoptotic regulatory molecules in diverse cancers, including MM, contributes to drug resistance. Importantly, the activity of a number of these proteins is modulated by MEK/ERK signalling. For example, ERK-mediated phosphorylation of the antiapoptotic molecule, Mcl-1, decreases its degradation, thereby promoting cell survival.<sup><a href="#bib33" rid="bib33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973048">33</a></sup> With the overexpression of Mcl-1, a common feature of MM associated with greater relapse and shorter survival,<sup><a href="#bib34" rid="bib34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973058">34</a></sup> constitutive MEK/ERK activity almost certainly contributes to elevated Mcl-1 expression in those MM with lesions in the Ras/ERK pathway. In contrast, Bim, a proapoptotic Bcl-2 family member that can bind to and neutralize Mcl-1, is targeted by ERK phosphorylation for proteasome-dependent degradation.<sup><a href="#bib35" rid="bib35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973089">35</a></sup> Hence, constitutive ERK signalling is likely to contribute significantly to MM survival by stabilising Mcl-1 and diminishing Bim expression. The activity of other prosurvival (Bcl-2 and Bcl-xL) and proapoptotic (Bad) Bcl-2-like proteins, that are also known to be regulated by ERK signalling, represent additional candidates that may contribute to the enhanced survival of MM cells.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">MEK inhibitors</h3><p id="__p14" class="p p-first-last">MEK1 and MEK2 are homologous dual specificity kinases that share ERK as their only known catalytic substrate,<sup><a href="#bib15" rid="bib15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973127">15</a></sup> making MEK an appealing target for cancer drug development. Although many kinase inhibitors target the ATP-binding region of an enzyme, MEK contains a hydrophobic allosteric pocket adjacent to the ATP-binding site that is not shared with other kinases.<sup><a href="#bib36" rid="bib36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973056">36</a></sup> This offers the opportunity to design highly selective inhibitors of MEK that do not simply target the conserved ATP region of the kinase. In the remainder of the review, we describe some of the various MEK inhibitors currently being investigated and their future role in cancer therapy.</p></div><div id="__sec5" class="sec"><h3 id="__sec5title">Prototypic MEK inhibitors</h3><p id="__p15" class="p p-first">Despite demonstrating <em>in vitro</em> activity, major <em>in vivo</em> limitations were identified for the early first generation MEK inhibitors, PD098059<sup><a href="#bib37" rid="bib37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973052">37</a></sup> and U0126.<sup><a href="#bib38" rid="bib38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973054">38</a></sup> Although both compounds were deemed unsuitable for clinical consideration they have proven to be invaluable tools for investigating the Ras/MAPK pathway. CI-1040 (PD184352) was the first MEK inhibitor to demonstrate tumour inhibitory activity <em>in vivo</em>.<sup><a href="#bib39" rid="bib39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973045">39</a></sup> Encouraging phase I results in advanced cancer patients, where one patient with pancreatic cancer achieved a partial response (PR) lasting 12 months, prompted a phase II study of CI-1040 in patients with advanced solid tumours.<sup><a href="#bib40" rid="bib40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973074">40</a></sup> However, in contrast to the phase I trial, no PR was observed.<sup><a href="#bib41" rid="bib41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973049">41</a></sup> As a result of its weak antitumour activity, development of CI-1040 was terminated in favour of the more potent PD0325901.</p><p id="__p16" class="p p-last">Compared with CI-1040, PD0325901 demonstrates significantly improved potency in cell-based assays (100-fold), oral bioavailability and metabolic stability.<sup><a href="#bib42" rid="bib42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973081">42</a></sup> Phase I investigation of PD0325901 was conducted in 66 advanced cancer patients. Three of 48 evaluable patients with melanoma achieved PR, while 10 had stable disease (s.d.) for &#x02a7e;4 months. A subset of these patients developed retinal vein occlusion.<sup><a href="#bib43" rid="bib43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973114">43</a></sup> A phase II study of PD0325901 was assessed in 34 advanced non-small cell lung carcinoma patients, but was eventually terminated owing to lack of objective responses and increasing concerns about ocular function and neurotoxicity at therapeutic doses.<sup><a href="#bib44" rid="bib44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973098">44</a></sup> Investigation of these treatment-related toxicities was conducted in animal models, where PD0325901 was found to cause retinal vein occlusion in rabbits. This adverse effect was attributed to the abrogation of phosphorylated-ERK (p-ERK) within the brain.<sup><a href="#bib45" rid="bib45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973069">45</a></sup> In light of these observations, development of PD0325901 has been suspended.</p></div><div id="__sec6" class="sec"><h3 id="__sec6title">MEK inhibitors in development</h3><p id="__p17" class="p p-first">AZD6244/ARRY-142886 (selumetinib) is a potent MEK inhibitor that has demonstrated significant tumour suppressive activity in a number of preclinical solid tumour models.<sup><a href="#bib46" rid="bib46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973073">46</a>, <a href="#bib47" rid="bib47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973053">47</a>, <a href="#bib48" rid="bib48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973118">48</a></sup> In cell-based enzymatic assays, AZD6244 inhibited purified MEK at an IC<sub>50</sub> of 14.1&#x000b1;0.79&#x02009;nM, with no inhibition observed at 10&#x02009;&#x003bc;&#x02133; against 40 other kinases. Cell lines harbouring oncogenic B-Raf and N-Ras mutations displayed enhanced sensitivity to AZD6244, whereas K-Ras mutated tumours showed variable responsiveness.<sup><a href="#bib47" rid="bib47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973107">47</a></sup> In 2004, a total of 57 patients with advanced cancer were treated in a phase I evaluation of AZD6244. The best clinical response achieved was s.d. &#x02a7e; for 5 months in 9 patients, with 2 patients maintaining s.d. for 19 and 22 months. Similar to PD0325901, blurred vision was reported in 7 patients; however, neurotoxicity was not observed.<sup><a href="#bib49" rid="bib49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973085">49</a></sup> Several phase II trials have since examined the effectiveness of AZD6244 in a diverse range of solid tumours.<sup><a href="#bib50" rid="bib50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973141">50</a>, <a href="#bib51" rid="bib51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973062">51</a>, <a href="#bib52" rid="bib52" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973112">52</a></sup> In each of these studies, the efficacy and tolerability of AZD6244 was compared with a conventional chemotherapeutic agent. However, even though some objective responses were observed, AZD6244 failed to demonstrate superior clinical responses over established treatment modalities. As a result of these studies there has not been an advocacy for AZD6244 as a monotherapy.</p><p id="__p18">AS703026/MSC1935369 demonstrates IC<sub>50</sub> values in the subnanomolar range and potently inhibits tumour growth <em>in vivo.</em><sup><a href="#bib53" rid="bib53" class=" bibr popnode">53</a></sup> Eighty-five advanced cancer patients were recruited for the phase I trial of AS703026. Visual disturbances were reported in a subset of patients, including some cases of serous macular detachment. Tumour shrinkage was witnessed in four melanoma patients, three of whom (all bearing B-Raf mutations) demonstrated PR.<sup><a href="#bib54" rid="bib54" class=" bibr popnode">54</a></sup></p><p id="__p19">XL-518/GDC-0973 is a potent, orally bioavailable inhibitor that blocks MEK1 function with an IC<sub>50</sub>&#x0003c;1&#x02009;n&#x02133; in enzymatic assays measuring ERK phosphorylation. Pharmacodynamic studies have demonstrated that a single dose of GDC-0973 inhibits p-ERK in xenograft tumours for up to 48&#x02009;h. In contrast to PD0325901, p-ERK levels in mouse brain tissue were not significantly suppressed following the administration of GDC-0973, suggesting reduced potential for adverse CNS events.<sup><a href="#bib55" rid="bib55" class=" bibr popnode">55</a></sup> A phase I study of GDC-0972 in patients with solid tumour was initiated in 2007. Confirmed PR were witnessed in three melanoma patients, two of which harboured B-Raf V600E mutations. Six patients with prolonged s.d. (&#x02a7e;5 months) have been observed to date.<sup><a href="#bib56" rid="bib56" class=" bibr popnode">56</a></sup></p><p id="__p20">The MEK inhibitor, BAY869766/RDEA119, specifically inhibits MEK1 (IC<sub>50</sub>=19&#x02009;n&#x02133;) and MEK2 (IC<sub>50</sub>=47&#x02009;n&#x02133;) when compared with 205 other kinases. The antitumour effect of BAY8697655 has been established in mouse xenograft models, with potent growth inhibition observed during drug treatment.<sup><a href="#bib57" rid="bib57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973120">57</a></sup> Early data from the BAY8679655 phase I trial demonstrates good drug tolerability, with rash being the most prevalent treatment-related adverse effect. Among the 69 advanced cancer patients enroled in the trial, 10 achieved s.d. with a mean duration of 10 months. Phase II development of BAY867966 is currently being pursued in light of these findings.<sup><a href="#bib58" rid="bib58" class=" bibr popnode">58</a></sup></p><p id="__p21" class="p p-last">GSK1120212 is a structurally novel allosteric MEK inhibitor with an <em>in vitro</em> IC<sub>50</sub> of 0.4&#x000b1;00.1&#x02009;n&#x02133; for MEK1 activation by B-Raf and 10&#x000b1;2&#x02009;n&#x02133; for p-MEK1 activity. In cell lines harbouring activating Ras or B-Raf mutations, GSK1120212 inhibited cell proliferation at IC<sub>50</sub> values &#x0003c;50&#x02009;n&#x02133;, but demonstrated decreased activity against those cells with wild-type Ras or wild-type-B-Raf.<sup><a href="#bib59" rid="bib59" class=" bibr popnode">59</a></sup> These results are consistent with other MEK inhibitors, where cells with constitutively active Ras/MAPK signalling demonstrate a reliance on these oncogenic pathways, thereby making them hypersensitive to MEK inhibition. In melanoma xenografted mouse models, GSK1120212 administered orally once daily demonstrated an effective t<sub>1/2</sub> of 36&#x02009;h with sustained suppression of p-ERK for &#x0003e;24&#x02009;h.<sup><a href="#bib60" rid="bib60" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973067">60</a></sup> Notably, inhibition of p-ERK was not observed within brain samples. Phase I results of this compound have recently been presented by Gordon <em>et al.</em><sup><a href="#bib61" rid="bib61" class=" bibr popnode">61</a></sup> For 22 patients with B-Raf mutant melanoma, 1 CR and 9 PR were observed. For 22 patients with pancreatic cancer, 1 PR and 9 s.d. were reported. Early data from a phase I/II trial examining GSK1120212 in patients with relapsed/refractory myeloid malignancies harbouring Ras mutations has also recently been reported. Patients were prospectively screened for K- and N-Ras mutations before receiving daily treatment with GSK1120212. Encouraging signs of clinical activity with manageable adverse effects have been observed.<sup><a href="#bib62" rid="bib62" class=" bibr popnode">62</a></sup></p></div><div id="__sec7" class="sec"><h3 id="__sec7title">Enhancing effectiveness with combination therapies</h3><p id="__p22" class="p p-first">Despite improvements in clinical potency and pharmacokinetics, MEK inhibitors have generally shown limited effectiveness as monotherapeutic agents. Several reasons may account for this observation.</p><p id="__p23">Abrogation of Ras/MAPK signalling appears to be mainly cytostatic, and suggests that an additional therapeutic modality is required to maximise the antitumour effectiveness of MEK inhibitors. In hepatocellular carcinoma xenograft models, AZD6244 in conjunction with doxorubicin demonstrated enhanced growth suppression (76&#x00025;&#x000b1;7), compared with AZD6244 (52&#x000b1;15&#x00025;) and doxorubicin (12&#x000b1;9&#x00025;) alone. This synergy was associated with increased apoptosis.<sup><a href="#bib63" rid="bib63" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973072">63</a></sup> Similar effects have been observed with AZD6244 and docetaxel in malignant melanoma,<sup><a href="#bib64" rid="bib64" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973077">64</a></sup> and AZD6244 and cytarabine in acute myelogenous leukaemia.<sup><a href="#bib65" rid="bib65" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973102">65</a></sup> The mechanism by which these agents cooperate is not entirely clear, but the available evidence suggests that many of these drugs can activate the Ras/MAPK pathway through diverse processes, thereby increasing the effectiveness of MEK inhibitors.<sup><a href="#bib66" rid="bib66" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973125">66</a></sup> However, the inhibitory effects of MEK on cell cycle progression may potentially reduce the effectiveness of many standard chemotherapeutic agents in combination therapy, due to the reliance of these agents on killing malignant cells that are rapidly dividing. Therefore, drug scheduling may have a critical role in the optimal utilisation of MEK inhibitors when combined with traditional chemotherapeutic drugs. In this regard, Yu <em>et al.</em><sup><a href="#bib67" rid="bib67" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973063">67</a></sup> have demonstrated that incubating leukaemic cells with paclitaxel before PD98059 exposure significantly increased cell death. In contrast, pretreatment with the MEK inhibitor reduced the susceptibility of cells to paclitaxel-induced apoptosis.</p><p id="__p24">Activating mutations within the Ras/MAPK network also contribute to the mechanisms of resistance to MEK inhibitors. A number of studies have demonstrated that oncogenic amplification of K-Ras and B-Raf confers decreased susceptibility to AZD6244.<sup><a href="#bib68" rid="bib68" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467616">68</a>, <a href="#bib69" rid="bib69" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467614">69</a></sup> Point mutations within MEK1 may also significantly attenuate the ability of MEK inhibitors to block ERK signalling in B-Raf V600E mutated tumours.<sup><a href="#bib70" rid="bib70" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973066">70</a></sup> These oncogenic events result in constitutive ERK pathway activation. In the absence of oncogenic Ras and Raf mutations, other oncogenic events that engage the Ras/MAPK pathway are also likely to stimulate normal feedback mechanisms that may increase the activity of various intermediaries in the Ras/MAPK signalling module, thereby promoting the ongoing activation of ERK kinase signalling.<sup><a href="#bib71" rid="bib71" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973080">71</a></sup> For either scenario, the activity of ERK and its target substrates may be maintained at levels that are sufficient to drive key cellular functions even in the presence of a MEK inhibitor. These observations suggest that targeting multiple nodes within the Ras/MAPK network may be a more efficacious clinical strategy than single target therapy.</p><p id="__p25">The contribution of multiple signalling networks to tumorigenesis also accounts for the limited responses seen with MEK inhibitors alone. For example, the phosphatidylinositol 3-kinase (PI3K/Akt/mTOR) and MAPK pathways share Ras as a common upstream effector.<sup><a href="#bib72" rid="bib72" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467617">72</a></sup> Consequently, activation of Ras, despite the downregulation of ERK activity by MKPs and SPRYs, could lead to compensatory signalling through this parallel network. Alternatively, oncogenic mutations within the PI3K/Akt axis may enhance MEK/ERK signal transduction. Indeed, dysregulation of the PI3K/Akt pathway has been shown to correlate with the decreased sensitivity to MEK inhibition.<sup><a href="#bib73" rid="bib73" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973109">73</a></sup> Predictably targeting both pathways simultaneously has proven effective in several studies. In AZD6244-resistant gastric cancer cell lines, activation of Akt through the EGFR/PI3K/Akt pathway was still observed following MEK inhibition. Blockade of this pathway using the EGFR inhibitor, gefitinib, synergistically enhanced tumour apoptosis <em>in vitro</em> and <em>in vivo</em>.<sup><a href="#bib74" rid="bib74" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973088">74</a></sup> Treatment of mutant murine lung cancers with the dual PI3K/mTOR inhibitor, NVP-BEZ235 and AZD6244 produced similar results.<sup><a href="#bib75" rid="bib75" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973099">75</a></sup> Recently, preliminary results from a phase I trial evaluating the combined activity of GDC-0973/XL-518 and the Akt inhibitor, GDC-0941, found that in a cohort of 27 advanced solid tumour patients, three patients achieved prolonged s.d. &#x02a7e;6 months when treated with both agents.<sup><a href="#bib76" rid="bib76" class=" bibr popnode">76</a></sup> Promising clinical activity has also been observed in the phase I trial of GSK1120212 in conjunction with the Akt inhibitor, GSK2141795.<sup><a href="#bib77" rid="bib77" class=" bibr popnode">77</a></sup> The number of preclinical and clinical studies investigating dual Ras/MAPK and PI3K/Akt inhibition indicates a growing trend to using these combinations to maximise antitumour response.</p><p id="__p26" class="p p-last">Aberrant signalling through additional kinase pathways may also contribute to MEK inhibitor resistance. For example, although non-small cell lung carcinomas carry both K-Ras and PTEN mutations, resistance of these cell lines to AZD6244 coincides with activation of the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT) following MEK inhibition.<sup><a href="#bib78" rid="bib78" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973140">78</a></sup> AZD6244 combined with STAT3 inhibition synergistically induced apoptosis in these cells. This effect can be explained by STAT3 suppressing the proapoptotic protein Bim through upregulation of miRNA-17, which antagonises the Bim expression induced by AZD6244.<sup><a href="#bib79" rid="bib79" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973059">79</a></sup> Collectively, these results provide a rationale for combining inhibitors of the JAK/STAT pathway and MEK inhibitors to reduce the potential impact of drug resistance. Information about the use of MEK inhibitors and other kinase pathway inhibitors is unknown.</p></div><div id="__sec8" class="sec"><h3 id="__sec8title">The role of MEK inhibitors in MM</h3><p id="__p27" class="p p-first">The advent of novel anti-MM agents has improved the management and prognosis of MM. With the immunomodulatory drugs, thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib, able to abrogate the survival advantage created by the BMME, current research has focussed on combining these novel therapies to improve patient outcomes.<sup><a href="#bib80" rid="bib80" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467619">80</a></sup> To date, promising results have been obtained in several clinical trials.<sup><a href="#bib81" rid="bib81" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973131">81</a>, <a href="#bib82" rid="bib82" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467618">82</a></sup> However, despite the clinical success of thalidomide, lenalidomide and bortezomib, a subset of patients do not initially respond to or ultimately become refractory to these agents.<sup><a href="#bib83" rid="bib83" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973106">83</a></sup> This emphasises the need for innovative anti-MM therapies.</p><p id="__p28">The impact of AZD6244 has been investigated in MM cells within the BMME.<sup><a href="#bib84" rid="bib84" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973079">84</a></sup> This compound specifically abrogated constitutive and cytokine-stimulated ERK phosphorylation and induced cytotoxicity in a panel of human myeloma cell lines (HMCL). Responses to AZD6244 were also witnessed in tumour cells derived from MM patients with advanced disease. These results suggest that AZD6244 is effective at advanced stages of disease, where MM cells are less reliant on the growth factors produced by the BMME. Furthermore, culturing of HMCL and patient-derived samples in the presence of exogenous interleukin-6 or bone marrow stromal cells did not protect against AZD6244-induced apoptosis. Synergistically enhanced cell death was noted in combinations of AZD6244 with conventional (dexamethasone) and novel (bortezomib, lenalidomide, perifisone) anti-MM agents. AZD6244 as a single agent was also examined in an <em>in vivo</em> human plasmocytoma xenograft model and demonstrated prolonged survival when compared with control animals. Breitkreutz <em>et al.</em><sup><a href="#bib85" rid="bib85" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973122">85</a></sup> have also investigated the consequences of AZD6244 administration on osteoclast differentiation, function and cytokine secretion in MM. AZD6244 blocked osteoclast differentiation and bone reabsorption in a dose-dependent manner. Furthermore, critical MM growth factors produced by the BMME, including interleukin-6, BAFF, APRIL and MIP-1&#x003b1; were all significantly reduced following AZD6244 treatment. Taken together, these results indicate that AZD6244 is able to abrogate paracrine signal dependent MM cell survival within the bone marrow niche. Both these studies provide a preclinical rationale for the further evaluation of AZD6244. A phase II trial examining the compound in MM is presently ongoing.</p><p id="__p29">Treatment with AS703026 has also been explored in MM.<sup><a href="#bib86" rid="bib86" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973105">86</a></sup> AS703026 inhibits HMCL and cytokine-induced osteoclast differentiation more potently (9- to 10-fold) than AZD6244, with an IC<sub>50</sub> ranging from 0.005&#x02013;2&#x02009;&#x003bc;&#x02133;. No discernable relationship between Ras or Raf mutational status and the sensitivity of HMCL to AS703026 was observed. This compound also induced apoptosis in HMCL cultured in the presence of bone marrow stromal cells. Further evaluation of AS703026 in conjunction with conventional (dexamethasone, melphalan) and novel (lenalidomide, bortezomib, perifisone, rapamycin) anti-MM therapies revealed synergistic cytotoxicity against HMCL and patient samples. Lastly, for tumour cells isolated from patients with relapsed/refractory MM treated with AS703026 at concentrations below 200&#x02009;n&#x02133;, dose-dependent cytotoxicity was observed for 15 of 18 patient MM samples. In this cohort of MM patient samples, while six and two of the patient samples harboured K-Ras/N-Ras and B-Raf mutations, respectively, the presence or absence of Ras or B-Raf mutations did not correlate with the sensitivity to MEK inhibition by AS703026.</p><p id="__p30">Despite these encouraging findings, outcomes from solid tumour models suggest that combination regimes are required to maximise the effectiveness of MEK inhibitors in MM. AZD6244 and AS703026 have demonstrated improved potency when used in combination with other anti-MM agents.<sup><a href="#bib84" rid="bib84" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973124">84</a>, <a href="#bib85" rid="bib85" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973116">85</a>, <a href="#bib86" rid="bib86" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973101">86</a></sup> The contribution of additional signalling pathways to MM tumorigenesis also offers the opportunity to target MEK in conjunction with the inhibition of these biochemical networks. Chatterjee <em>et al.</em><sup><a href="#bib30" rid="bib30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973083">30</a></sup> have determined that the combined disruption of the Ras/MAPK and JAK/STAT pathway is required to induce MM apoptosis in the presence of bone marrow stromal cells. Similarly, the contribution PI3K/Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF&#x003ba;B) pathway deregulation exerts on MM and drug resistance also makes these pathways attractive targets for co-inhibition with MEK specific agents.<sup><a href="#bib5" rid="bib5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973130">5</a>, <a href="#bib29" rid="bib29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973111">29</a></sup></p><p id="__p31" class="p p-last">Several other small molecule inhibitors have also recently emerged as promising therapies in MM. Histone deacetylases (HDAC) represent a family of enzymes that control transcription by modifying histones. Overexpression of HDAC in MM prevents the transcription of various tumour-suppressor genes, which in turn enhances cellular proliferation and represses cell death.<sup><a href="#bib87" rid="bib87" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973070">87</a></sup> Inhibition of HDAC activity reverses these outcomes, culminating in the accumulation of acetylated histones that promote the apoptosis of malignant cells.<sup><a href="#bib88" rid="bib88" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973121">88</a></sup> Clinical evaluation of the HDAC inhibitors as single agents in relapsed/refractory MM patients has yielded modest response rates.<sup><a href="#bib89" rid="bib89" class=" bibr popnode">89</a>, <a href="#bib90" rid="bib90" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973123">90</a></sup> Nevertheless, several studies have reported a significant increase in the anti-MM effect of these agents, when used in conjunction with conventional anti-MM chemotherapeutics,<sup><a href="#bib91" rid="bib91" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973115">91</a></sup> lenalidomide and bortezomib.<sup><a href="#bib92" rid="bib92" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973044">92</a></sup> Combinations of MEK and HDAC inhibitors have been limited to preclinical studies involving chronic myelogenous leukaemia and non-small cell lung carcinoma cell lines, but preliminary results have been promising.<sup><a href="#bib93" rid="bib93" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973065">93</a>, <a href="#bib94" rid="bib94" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973129">94</a></sup> Heat shock protein 90 (HSP90) is a molecular chaperone that regulates many of the proteins involved in Ras/MAPK, PI3K/Akt, JAK/STAT and NF&#x003ba;B signalling, as well other biochemical pathways that control apoptosis and cell cycle progression.<sup><a href="#bib95" rid="bib95" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_337467615">95</a></sup> Consistent with these properties, inhibition of HSP90 has been shown to disrupt multiple pathways crucial to MM survival.<sup><a href="#bib96" rid="bib96" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973128">96</a>, <a href="#bib97" rid="bib97" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973142">97</a></sup> While co-treatment of MM cells with a MEK and HSP90 inhibitors might serve as a means of attenuating the feedback mechanisms that promote resistance to MEK inhibitors, the clinical efficacy of these approaches is dependent upon how selective and active these combination regimes are <em>in vivo</em>. In particular, the potential interrupting multiple kinase networks has for increasing the likelihood of adverse effects and drug toxicity is likely to be an important factor in determining the optimal use of these agents.</p></div><div id="__sec9" class="sec sec-last"><h3 id="__sec9title">Predicting patient responses to MEK inhibitors: identification of relevant biomarkers</h3><p id="__p32" class="p p-first">As all MEK inhibitors tested to date demonstrate potent and selective activity against MEK1/2, toxicity profiles and drug exposure are likely to be the key criteria that refine these drugs for therapeutic use. Furthermore, it has become clear that certain genetic sub-types in solid tumours are associated with increased susceptibility or resistance to MEK inhibitors. This observation highlights the need for a reliable marker of responsiveness to MEK inhibitors, allowing tailoring of individualised therapies and reducing the occurrence of adverse events.</p><p id="__p33">Currently it remains difficult to determine which patients will benefit most from MEK inhibitor treatment. Whilst activating B-Raf mutations are associated with exquisite sensitivity against these agents, other biochemical markers demonstrate less predictability. For example, the poor correlation between MEK inhibitor susceptibility Ras genotypes and p-ERK expression is well documented.<sup><a href="#bib12" rid="bib12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973117">12</a>, <a href="#bib41" rid="bib41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973046">41</a>, <a href="#bib46" rid="bib46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973133">46</a>, <a href="#bib47" rid="bib47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973095">47</a>, <a href="#bib48" rid="bib48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973143">48</a>, <a href="#bib60" rid="bib60" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973076">60</a></sup> In one study, analysis of transcriptional pathway signatures in various solid tumours, identified a panel of 18 genes, the expression of which correlated with responsiveness to AZD6244.<sup><a href="#bib98" rid="bib98" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973071">98</a></sup> This signature contained transcriptional targets of ERK involved in negative-feedback regulation (DUSP4/6 and SPRY2), members of the Ets family of transcription factors (ETV4, ETV5 and ELF1) and other genes associated with MAPK signalling, cell cycle progression and tumour prognosis. A 13-gene signature was also identified that was predictive of resistance to AZD6244. This diverse set of genes shared common links with transforming growth factor-&#x003b2; (TGF-&#x003b2;), tumour necrosis factor-&#x003b1; and NF&#x003ba;B signalling. The role of these genes in MM and their potential predictive value for MEK inhibitor responsiveness has not been appraised.</p><p id="__p34" class="p p-last">Recent data published by Annuziata <em>et al.</em><sup><a href="#bib99" rid="bib99" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304973134">99</a></sup> has reported the use of the musculoaponeurotic fibrosarcoma (MAF) oncogene as a potential biomarker for MEK inhibitor responses in MM. In approximately 10&#x00025; of cases, aberrant MAF expression is due to a (14;16) translocation. High levels of MAF were also observed in patient samples with t(4;14) translocations. Both t(4:16) and t(4;14) translocations correlate with disease progression and worse overall survival. The MEK/ERK pathway was found to regulate transcription of the MAF proto-oncogene through ERK activation of FOS, a finding consistent with MAF protein and mRNA levels being downregulated following MEK inhibition. To examine the dependence of MM cells on MEK/ERK signalling, U0126 was administered to 16 HMCL that represented the heterogeneous onco-genetics of the disease. Of the 10 HMCL killed by this MEK inhibitor in a dose-dependent manner, 9 cell lines exhibited a t(4;16) or t(4;14) translocation and over expressed MAF. Moreover, the cytotoxic effect of U0126 was not neutralised by the presence of bone marrow stromal cells and remarkably, the impact of MEK inhibition on MM viability could be rescued by exogenous MAF expression. Importantly, this study provides a mechanistic rationale for using MEK inhibitor therapy in MM patients that overexpress c-MAF. These findings emphasise the potential benefit of genetic profiling to identify patients with MAF-expressing MM who may benefit from this class of agents. As part of the phase II trial of AZD6244 in relapsed/refractory MM, extensive molecular profiling of a subset of patients was conducted to correlate the genetic characteristics of MM with clinical outcomes. To date, detailed clinical data from eight patients has been analysed, four of whom overexpress c-MAF or MAF-B. One patient (fibroblast growth factor receptor 3) had a very good PR lasting 8 months. Another patient (MAF-B) had a PR of 6 months. Finally, two patients (one MAF-B, one pending results) demonstrated s.d. of &#x0003e;5 and 13 months, respectively.<sup><a href="#bib100" rid="bib100" class=" bibr popnode">100</a></sup> Additional studies with larger sample sizes are required to support or refute MAF expression as a reliable biomarker for MEK inhibition.</p></div></div><div id="__sec10" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec10title">Conclusion</h2><p id="__p35" class="p p-first-last">The Ras/Raf/MEK/ERK pathway has an established role in the various neoplastic phenotypes observed in many malignancies. Deregulation of this pathway is also a common feature of MM, and contributes to the relapsing and refractory nature of the disease. These observations make this pathway an attractive target for pharmaceutical investigation, with a number of MEK inhibitors having been developed and evaluated clinically. Although preclinical studies of MEK inhibitors in MM have demonstrated a capacity to induce MM apoptosis by overcoming the prosurvival effects of the BMME, solid tumour studies indicate that the therapeutic benefit of MEK inhibitors alone are likely to be of limited benefit. Therefore, future clinical approaches require a shift towards using MEK inhibitors in combination with current anti-MM compounds and other novel small molecule inhibitors. The identification of relevant biomarkers of MEK inhibitor responses remains a high priority that can be used to predict patient sensitivity and to tailor individualised therapies.</p></div><div id="notes-1" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-1title">Notes</h2><p id="__p36">The authors declare no conflict of interest</p></div><div id="ref-list-1" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-1title">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="bib1"><span class="mixed-citation">Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. <span><span class="ref-journal">Oncogene. </span>2007;<span class="ref-vol">26</span>:3279–3290.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17496922" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=MAP+kinase+signalling+pathways+in+cancer&amp;author=AS+Dhillon&amp;author=S+Hagan&amp;author=O+Rath&amp;author=W+Kolch&amp;volume=26&amp;publication_year=2007&amp;pages=3279-3290&amp;pmid=17496922&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib2"><span class="mixed-citation">McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <span><span class="ref-journal">Biochim Biophys Acta. </span>2007;<span class="ref-vol">1773</span>:1263–1284.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2696318/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17126425" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochim+Biophys+Acta&amp;title=Roles+of+the+Raf/MEK/ERK+pathway+in+cell+growth,+malignant+transformation+and+drug+resistance&amp;author=JA+McCubrey&amp;author=LS+Steelman&amp;author=WH+Chappell&amp;author=SL+Abrams&amp;author=EWT+Wong&amp;volume=1773&amp;publication_year=2007&amp;pages=1263-1284&amp;pmid=17126425&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib3"><span class="mixed-citation">Morabito F, Gentile M, Mazzone C, Bringhen S, Vigna E, Lucia E, et al. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. <span><span class="ref-journal">Eur J Haematol. </span>2010;<span class="ref-vol">85</span>:181–191.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20491882" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Haematol&amp;title=Therapeutic+approaches+for+newly+diagnosed+multiple+myeloma+patients+in+the+era+of+novel+drugs&amp;author=F+Morabito&amp;author=M+Gentile&amp;author=C+Mazzone&amp;author=S+Bringhen&amp;author=E+Vigna&amp;volume=85&amp;publication_year=2010&amp;pages=181-191&amp;pmid=20491882&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib4"><span class="mixed-citation">Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">108</span>:2020–2028.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1895543/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16728703" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The+molecular+classification+of+multiple+myeloma&amp;author=F+Zhan&amp;author=Y+Huang&amp;author=S+Colla&amp;author=JP+Stewart&amp;author=I+Hanamura&amp;volume=108&amp;publication_year=2006&amp;pages=2020-2028&amp;pmid=16728703&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib5"><span class="mixed-citation">Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <span><span class="ref-journal">Nat Rev Cancer. </span>2007;<span class="ref-vol">7</span>:585–598.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17646864" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Understanding+multiple+myeloma+pathogenesis+in+the+bone+marrow+to+identify+new+therapeutic+targets&amp;author=T+Hideshima&amp;author=C+Mitsiades&amp;author=G+Tonon&amp;author=PG+Richardson&amp;author=KC+Anderson&amp;volume=7&amp;publication_year=2007&amp;pages=585-598&amp;pmid=17646864&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib6"><span class="mixed-citation">Malumbres M, Barbacid M. RAS oncogenes: The first 30 years. <span><span class="ref-journal">Nat Rev Cancer. </span>2003;<span class="ref-vol">3</span>:459–465.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12778136" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=RAS+oncogenes:+The+first+30+years&amp;author=M+Malumbres&amp;author=M+Barbacid&amp;volume=3&amp;publication_year=2003&amp;pages=459-465&amp;pmid=12778136&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib7"><span class="mixed-citation">Boguski MS, McCormick F. Proteins regulating Ras and its relatives. <span><span class="ref-journal">Nature. </span>1993;<span class="ref-vol">366</span>:643–654.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8259209" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Proteins+regulating+Ras+and+its+relatives&amp;author=MS+Boguski&amp;author=F+McCormick&amp;volume=366&amp;publication_year=1993&amp;pages=643-654&amp;pmid=8259209&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib8"><span class="mixed-citation">Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. <span><span class="ref-journal">Oncogene. </span>1999;<span class="ref-vol">18</span>:813–822.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9989833" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Constitutive+activation+of+the+41-/43-kDa+mitogen-activated+protein+kinase+signaling+pathway+in+human+tumors&amp;author=R+Hoshino&amp;author=Y+Chatani&amp;author=T+Yamori&amp;author=T+Tsuruo&amp;author=H+Oka&amp;volume=18&amp;publication_year=1999&amp;pages=813-822&amp;pmid=9989833&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib9"><span class="mixed-citation">Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. <span><span class="ref-journal">Mol Cell Biol. </span>1995;<span class="ref-vol">15</span>:6430–6442.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC230894/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7565795" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=Conditionally+oncogenic+forms+of+the+A-Raf+and+B-Raf+protein+kinases+display+different+biological+and+biochemical+properties+in+NIH+3T3+cells&amp;author=CA+Pritchard&amp;author=ML+Samuels&amp;author=E+Bosch&amp;author=M+McMahon&amp;volume=15&amp;publication_year=1995&amp;pages=6430-6442&amp;pmid=7565795&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib10"><span class="mixed-citation">Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:4378–4383.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9020159" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Differential+regulation+of+Raf-1,+A-Raf,+and+B-Raf+by+oncogenic+Ras+and+tyrosine+kinases&amp;author=R+Marais&amp;author=Y+Light&amp;author=HF+Paterson&amp;author=CS+Mason&amp;author=CJ+Marshall&amp;volume=272&amp;publication_year=1997&amp;pages=4378-4383&amp;pmid=9020159&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib11"><span class="mixed-citation">Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. <span><span class="ref-journal">Nature. </span>2002;<span class="ref-vol">417</span>:949–954.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12068308" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Mutations+of+the+BRAF+gene+in+human+cancer&amp;author=H+Davies&amp;author=GR+Bignell&amp;author=C+Cox&amp;author=P+Stephens&amp;author=S+Edkins&amp;volume=417&amp;publication_year=2002&amp;pages=949-954&amp;pmid=12068308&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib12"><span class="mixed-citation">Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">439</span>:358–362.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3306236/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16273091" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&amp;author=DB+Solit&amp;author=LA+Garraway&amp;author=CA+Pratilas&amp;author=A+Sawai&amp;author=G+Getz&amp;volume=439&amp;publication_year=2006&amp;pages=358-362&amp;pmid=16273091&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib13"><span class="mixed-citation">Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G, et al. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. <span><span class="ref-journal">Leukemia. </span>2003;<span class="ref-vol">17</span>:2238–2240.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12931219" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=BRAF+gene+is+not+mutated+in+plasma+cell+leukemia+and+multiple+myeloma&amp;author=L+Bonello&amp;author=C+Voena&amp;author=M+Ladetto&amp;author=M+Boccadoro&amp;author=G+Palestro&amp;volume=17&amp;publication_year=2003&amp;pages=2238-2240&amp;pmid=12931219&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib14"><span class="mixed-citation">Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74(raf-1) <span><span class="ref-journal">EMBO J. </span>1994;<span class="ref-vol">13</span>:1610–1619.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC394991/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8157000" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J&amp;title=Identification+of+the+sites+in+MAP+kinase+kinase-1+phosphorylated+by+p74(raf-1)&amp;author=DR+Alessi&amp;author=Y+Saito&amp;author=DG+Campbell&amp;author=P+Cohen&amp;author=G+Sithanandam&amp;volume=13&amp;publication_year=1994&amp;pages=1610-1619&amp;pmid=8157000&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib15"><span class="mixed-citation">Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. <span><span class="ref-journal">Cell. </span>1991;<span class="ref-vol">65</span>:663–675.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2032290" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=ERKs:+a+family+of+protein-serine/threonine+kinases+that+are+activated+and+tyrosine+phosphorylated+in+response+to+insulin+and+NGF&amp;author=TG+Boulton&amp;author=SH+Nye&amp;author=DJ+Robbins&amp;author=NY+Ip&amp;author=E+Radziejewska&amp;volume=65&amp;publication_year=1991&amp;pages=663-675&amp;pmid=2032290&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib16"><span class="mixed-citation">Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. <span><span class="ref-journal">Growth Factors. </span>2006;<span class="ref-vol">24</span>:21–44.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16393692" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Growth+Factors&amp;title=The+extracellular+signal-regulated+kinase:+multiple+substrates+regulate+diverse+cellular+functions&amp;author=S+Yoon&amp;author=R+Seger&amp;volume=24&amp;publication_year=2006&amp;pages=21-44&amp;pmid=16393692&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib17"><span class="mixed-citation">Kim HJ, Bar-Sagi D. Modulation of signalling by sprouty: a developing story. <span><span class="ref-journal">Nat Rev Mol Cell Biol. </span>2004;<span class="ref-vol">5</span>:441–450.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15173823" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Mol+Cell+Biol&amp;title=Modulation+of+signalling+by+sprouty:+a+developing+story&amp;author=HJ+Kim&amp;author=D+Bar-Sagi&amp;volume=5&amp;publication_year=2004&amp;pages=441-450&amp;pmid=15173823&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib18"><span class="mixed-citation">Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. <span><span class="ref-journal">Cancer Metastasis Rev. </span>2008;<span class="ref-vol">27</span>:253–261.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18330678" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Metastasis+Rev&amp;title=Dual-specificity+MAP+kinase+phosphatases+(MKPs)+and+cancer&amp;author=SM+Keyse&amp;volume=27&amp;publication_year=2008&amp;pages=253-261&amp;pmid=18330678&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib19"><span class="mixed-citation">Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. <span><span class="ref-journal">FASEB J. </span>2000;<span class="ref-vol">14</span>:6–16.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10627275" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J&amp;title=Dual+specificity+phosphatases:+a+gene+family+for+control+of+MAP+kinase+function&amp;author=M+Camps&amp;author=A+Nichols&amp;author=S+Arkinstall&amp;volume=14&amp;publication_year=2000&amp;pages=6-16&amp;pmid=10627275&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib20"><span class="mixed-citation">Udell CM, Rajakulendran T, Sicheri F, Therrien M. Mechanistic principles of RAF kinase signaling. <span><span class="ref-journal">Cell Mol Life Sci. </span>2011;<span class="ref-vol">68</span>:553–565.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20820846" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Mol+Life+Sci&amp;title=Mechanistic+principles+of+RAF+kinase+signaling&amp;author=CM+Udell&amp;author=T+Rajakulendran&amp;author=F+Sicheri&amp;author=M+Therrien&amp;volume=68&amp;publication_year=2011&amp;pages=553-565&amp;pmid=20820846&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib21"><span class="mixed-citation">Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, De Matos Simoes R, Carugo O, et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2009;<span class="ref-vol">16</span>:294–303.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19219045" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Struct+Mol+Biol&amp;title=A+Mek1-Mek2+heterodimer+determines+the+strength+and+duration+of+the+Erk+signal&amp;author=F+Catalanotti&amp;author=G+Reyes&amp;author=V+Jesenberger&amp;author=G+Galabova-Kovacs&amp;author=R+De+Matos+Simoes&amp;volume=16&amp;publication_year=2009&amp;pages=294-303&amp;pmid=19219045&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib22"><span class="mixed-citation">Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:729–736.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11157491" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Activated+fibroblast+growth+factor+receptor+3+is+an+oncogene+that+contributes+to+tumor+progression+in+multiple+myeloma&amp;author=M+Chesi&amp;author=LA+Brents&amp;author=SA+Ely&amp;author=C+Bais&amp;author=DF+Robbiani&amp;volume=97&amp;publication_year=2001&amp;pages=729-736&amp;pmid=11157491&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib23"><span class="mixed-citation">Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, et al. Ras oncogene mutation in multiple myeloma. <span><span class="ref-journal">J Exp Med. </span>1989;<span class="ref-vol">170</span>:1715–1725.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2189505/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2681517" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Ras+oncogene+mutation+in+multiple+myeloma&amp;author=A+Neri&amp;author=JP+Murphy&amp;author=L+Cro&amp;author=D+Ferrero&amp;author=C+Tarella&amp;volume=170&amp;publication_year=1989&amp;pages=1715-1725&amp;pmid=2681517&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib24"><span class="mixed-citation">Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">88</span>:2699–2706.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8839865" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Activating+mutations+of+N-+and+K-ras+in+multiple+myeloma+show+different+clinical+associations:+analysis+of+the+Eastern+Cooperative+Oncology+Group+phase+III+trial&amp;author=P+Liu&amp;author=T+Leong&amp;author=L+Quam&amp;author=D+Billadeau&amp;author=NE+Kay&amp;volume=88&amp;publication_year=1996&amp;pages=2699-2706&amp;pmid=8839865&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib25"><span class="mixed-citation">Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. <span><span class="ref-journal">Hum Mutat. </span>2001;<span class="ref-vol">18</span>:212–224.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11524732" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mutat&amp;title=High+incidence+of+N+and+K-Ras+activating+mutations+in+multiple+myeloma+and+primary+plasma+cell+leukemia+at+diagnosis&amp;author=S+Bezieau&amp;author=MC+Devilder&amp;author=H+Avet-Loiseau&amp;author=MP+Mellerin&amp;author=D+Puthier&amp;volume=18&amp;publication_year=2001&amp;pages=212-224&amp;pmid=11524732&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib26"><span class="mixed-citation">Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. <span><span class="ref-journal">Eur J Cancer. </span>2006;<span class="ref-vol">42</span>:1574–1580.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16797970" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cancer&amp;title=Signalling+and+survival+pathways+in+multiple+myeloma&amp;author=K+Bommert&amp;author=RC+Bargou&amp;author=T+Stuhmer&amp;volume=42&amp;publication_year=2006&amp;pages=1574-1580&amp;pmid=16797970&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib27"><span class="mixed-citation">Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, et al. Clinical and biological significance of RAS mutations in multiple myeloma. <span><span class="ref-journal">Leukemia. </span>2008;<span class="ref-vol">22</span>:2280–2284.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3864109/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18528420" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Clinical+and+biological+significance+of+RAS+mutations+in+multiple+myeloma&amp;author=WJ+Chng&amp;author=N+Gonzalez-Paz&amp;author=T+Price-Troska&amp;author=S+Jacobus&amp;author=SV+Rajkumar&amp;volume=22&amp;publication_year=2008&amp;pages=2280-2284&amp;pmid=18528420&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib28"><span class="mixed-citation">Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:317–323.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15339850" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Possible+roles+for+activating+RAS+mutations+in+the+MGUS+to+MM+transition+and+in+the+intramedullary+to+extramedullary+transition+in+some+plasma+cell+tumors&amp;author=T+Rasmussen&amp;author=M+Kuehl&amp;author=M+Lodahl&amp;author=HE+Johnsen&amp;author=IMS+Dahl&amp;volume=105&amp;publication_year=2005&amp;pages=317-323&amp;pmid=15339850&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib29"><span class="mixed-citation">Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, D&#x000f6;rken B, et al. P13-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. <span><span class="ref-journal">Leukemia. </span>2004;<span class="ref-vol">18</span>:1883–1890.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15356648" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=P13-K/AKT/FKHR+and+MAPK+signaling+cascades+are+redundantly+stimulated+by+a+variety+of+cytokines+and+contribute+independently+to+proliferation+and+survival+of+multiple+myeloma+cells&amp;author=S+Lentzsch&amp;author=M+Chatterjee&amp;author=M+Gries&amp;author=K+Bommert&amp;author=H+Gollasch&amp;volume=18&amp;publication_year=2004&amp;pages=1883-1890&amp;pmid=15356648&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib30"><span class="mixed-citation">Chatterjee M, St&#x000fc;hmer T, Herrmann P, Bommert K, D&#x000f6;rken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>:3712–3721.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15297310" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Combined+disruption+of+both+the+MEK/ERK+and+the+IL-6R/STAT3+pathways+is+required+to+induce+apoptosis+of+multiple+myeloma+cells+in+the+presence+of+bone+marrow+stromal+cells&amp;author=M+Chatterjee&amp;author=T+St&#x000fc;hmer&amp;author=P+Herrmann&amp;author=K+Bommert&amp;author=B+D&#x000f6;rken&amp;volume=104&amp;publication_year=2004&amp;pages=3712-3721&amp;pmid=15297310&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib31"><span class="mixed-citation">Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1993;<span class="ref-vol">90</span>:2251–2255.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC46064/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7681591" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Tumor+progression+locus+2+(Tpl-2)+encodes+a+protein+kinase+involved+in+the+progression+of+rodent+T-cell+lymphomas+and+in+T-cell+activation&amp;author=C+Patriotis&amp;author=A+Makris&amp;author=SE+Bear&amp;author=PN+Tsichlis&amp;volume=90&amp;publication_year=1993&amp;pages=2251-2255&amp;pmid=7681591&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib32"><span class="mixed-citation">Gantke T, Sriskantharajah S, Sadowski M, Ley SC. I&#x003ba;B kinase regulation of the TPL-2/ERK MAPK pathway. <span><span class="ref-journal">Immunol Rev. </span>2012;<span class="ref-vol">246</span>:168–182.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22435554" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunol+Rev&amp;title=I&#x003ba;B+kinase+regulation+of+the+TPL-2/ERK+MAPK+pathway&amp;author=T+Gantke&amp;author=S+Sriskantharajah&amp;author=M+Sadowski&amp;author=SC+Ley&amp;volume=246&amp;publication_year=2012&amp;pages=168-182&amp;pmid=22435554&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib33"><span class="mixed-citation">Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. <span><span class="ref-journal">Oncogene. </span>2004;<span class="ref-vol">23</span>:5301–5315.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15241487" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=MCL1+is+phosphorylated+in+the+PEST+region+and+stabilized+upon+ERK+activation+in+viable+cells,+and+at+additional+sites+with+cytotoxic+okadaic+acid+or+taxol&amp;author=AM+Domina&amp;author=JA+Vrana&amp;author=MA+Gregory&amp;author=SR+Hann&amp;author=RW+Craig&amp;volume=23&amp;publication_year=2004&amp;pages=5301-5315&amp;pmid=15241487&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib34"><span class="mixed-citation">Wuill&#x000e8;me-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. <span><span class="ref-journal">Leukemia. </span>2005;<span class="ref-vol">19</span>:1248–1252.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15902294" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Mcl-1+is+overexpressed+in+multiple+myeloma+and+associated+with+relapse+and+shorter+survival&amp;author=S+Wuill&#x000e8;me-Toumi&amp;author=N+Robillard&amp;author=P+Gomez&amp;author=P+Moreau&amp;author=S+Le+Gouill&amp;volume=19&amp;publication_year=2005&amp;pages=1248-1252&amp;pmid=15902294&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib35"><span class="mixed-citation">Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:18811–18816.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12646560" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Activation+of+the+ERK1/2+signaling+pathway+promotes+phosphorylation+and+proteasome-dependent+degradation+of+the+BH3-only+protein,+Bim&amp;author=R+Ley&amp;author=K+Balmanno&amp;author=K+Hadfield&amp;author=C+Weston&amp;author=SJ+Cook&amp;volume=278&amp;publication_year=2003&amp;pages=18811-18816&amp;pmid=12646560&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib36"><span class="mixed-citation">Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2004;<span class="ref-vol">11</span>:1192–1197.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15543157" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Struct+Mol+Biol&amp;title=Structures+of+human+MAP+kinase+kinase+1+(MEK1)+and+MEK2+describe+novel+noncompetitive+kinase+inhibition&amp;author=JF+Ohren&amp;author=H+Chen&amp;author=A+Pavlovsky&amp;author=C+Whitehead&amp;author=E+Zhang&amp;volume=11&amp;publication_year=2004&amp;pages=1192-1197&amp;pmid=15543157&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib37"><span class="mixed-citation">Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1995;<span class="ref-vol">92</span>:7686–7689.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC41210/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7644477" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=A+synthetic+inhibitor+of+the+mitogen-activated+protein+kinase+cascade&amp;author=DT+Dudley&amp;author=L+Pang&amp;author=SJ+Decker&amp;author=AJ+Bridges&amp;author=AR+Saltiel&amp;volume=92&amp;publication_year=1995&amp;pages=7686-7689&amp;pmid=7644477&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib38"><span class="mixed-citation">Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:18623–18632.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9660836" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Identification+of+a+novel+inhibitor+of+mitogen-activated+protein+kinase+kinase&amp;author=MF+Favata&amp;author=KY+Horiuchi&amp;author=EJ+Manos&amp;author=AJ+Daulerio&amp;author=DA+Stradley&amp;volume=273&amp;publication_year=1998&amp;pages=18623-18632&amp;pmid=9660836&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib39"><span class="mixed-citation">Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors <em>in vivo</em>. <span><span class="ref-journal">Nat Med. </span>1999;<span class="ref-vol">5</span>:810–816.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10395327" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Blockade+of+the+MAP+kinase+pathway+suppresses+growth+of+colon+tumors+in+vivo&amp;author=JS+Sebolt-Leopold&amp;author=DT+Dudley&amp;author=R+Herrera&amp;author=K+Van+Becelaere&amp;author=A+Wiland&amp;volume=5&amp;publication_year=1999&amp;pages=810-816&amp;pmid=10395327&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib40"><span class="mixed-citation">LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. <span><span class="ref-journal">J Clin Oncol. </span>2005;<span class="ref-vol">23</span>:5281–5293.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16009947" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I+and+pharmacodynamic+study+of+the+oral+MEK+inhibitor+CI-1040+in+patients+with+advanced+malignancies&amp;author=PM+LoRusso&amp;author=AA+Adjei&amp;author=M+Varterasian&amp;author=S+Gadgeel&amp;author=J+Reid&amp;volume=23&amp;publication_year=2005&amp;pages=5281-5293&amp;pmid=16009947&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib41"><span class="mixed-citation">Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. <span><span class="ref-journal">J Clin Oncol. </span>2004;<span class="ref-vol">22</span>:4456–4462.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15483017" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Multicenter+phase+II+study+of+the+oral+MEK+inhibitor,+CI-1040,+in+patients+with+advanced+non-small-cell+lung,+breast,+colon,+and+pancreatic+cancer&amp;author=J+Rinehart&amp;author=AA+Adjei&amp;author=PM+LoRusso&amp;author=D+Waterhouse&amp;author=JR+Hecht&amp;volume=22&amp;publication_year=2004&amp;pages=4456-4462&amp;pmid=15483017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib42"><span class="mixed-citation">Brown AP, Carlson TCG, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. <span><span class="ref-journal">Cancer Chemother Pharmacol. </span>2007;<span class="ref-vol">59</span>:671–679.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16944149" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemother+Pharmacol&amp;title=Pharmacodynamic+and+toxicokinetic+evaluation+of+the+novel+MEK+inhibitor,+PD0325901,+in+the+rat+following+oral+and+intravenous+administration&amp;author=AP+Brown&amp;author=TCG+Carlson&amp;author=CM+Loi&amp;author=MJ+Graziano&amp;volume=59&amp;publication_year=2007&amp;pages=671-679&amp;pmid=16944149&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib43"><span class="mixed-citation">LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:1924–1937.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20215549" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+the+oral+MAPK/ERK+kinase+inhibitor+PD-0325901+in+patients+with+advanced+cancers&amp;author=PM+LoRusso&amp;author=SS+Krishnamurthi&amp;author=JJ+Rinehart&amp;author=LM+Nabell&amp;author=L+Malburg&amp;volume=16&amp;publication_year=2010&amp;pages=1924-1937&amp;pmid=20215549&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib44"><span class="mixed-citation">Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:2450–2457.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20332327" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=A+phase+II+study+of+PD-0325901,+an+oral+MEK+inhibitor,+in+previously+treated+patients+with+advanced+non-small+cell+lung+cancer&amp;author=EB+Haura&amp;author=AD+Ricart&amp;author=TG+Larson&amp;author=PJ+Stella&amp;author=L+Bazhenova&amp;volume=16&amp;publication_year=2010&amp;pages=2450-2457&amp;pmid=20332327&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib45"><span class="mixed-citation">Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. <span><span class="ref-journal">J Ocul Pharmacol Ther. </span>2009;<span class="ref-vol">25</span>:519–530.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19929595" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Ocul+Pharmacol+Ther&amp;title=PD0325901,+a+mitogen-activated+protein+kinase+kinase+inhibitor,+produces+ocular+toxicity+in+a+rabbit+animal+model+of+retinal+vein+occlusion&amp;author=W+Huang&amp;author=AH+Yang&amp;author=D+Matsumoto&amp;author=W+Collette&amp;author=L+Marroquin&amp;volume=25&amp;publication_year=2009&amp;pages=519-530&amp;pmid=19929595&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib46"><span class="mixed-citation">Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <em>in vivo</em>, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. <span><span class="ref-journal">Mol Cancer Ther. </span>2007;<span class="ref-vol">6</span>:2209–2219.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17699718" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=AZD6244+(ARRY-142886),+a+potent+inhibitor+of+mitogen-activated+protein+kinase/extracellular+signal-regulated+kinase+kinase+1/2+kinases:+mechanism+of+action+in+vivo,+pharmacokinetic/pharmacodynamic+relationship,+and+potential+for+combination+in+preclinical+models&amp;author=BR+Davies&amp;author=A+Logie&amp;author=JS+McKay&amp;author=P+Martin&amp;author=S+Steele&amp;volume=6&amp;publication_year=2007&amp;pages=2209-2219&amp;pmid=17699718&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib47"><span class="mixed-citation">Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. <span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>:1576–1583.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17332304" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Biological+characterization+of+ARRY-142886+(AZD6244),+a+potent,+highly+selective+mitogen-activated+protein+kinase+kinase+1/2+inhibitor&amp;author=TC+Yeh&amp;author=V+Marsh&amp;author=BA+Bernat&amp;author=J+Ballard&amp;author=H+Colwell&amp;volume=13&amp;publication_year=2007&amp;pages=1576-1583&amp;pmid=17332304&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib48"><span class="mixed-citation">Huynh H, Soo KC, Chow PKH, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. <span><span class="ref-journal">Mol Cancer Ther. </span>2007;<span class="ref-vol">6</span>:138–146.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17237274" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Targeted+inhibition+of+the+extracellular+signal-regulated+kinase+kinase+pathway+with+AZD6244+(ARRY-142886)+in+the+treatment+of+hepatocellular+carcinoma&amp;author=H+Huynh&amp;author=KC+Soo&amp;author=PKH+Chow&amp;author=E+Tran&amp;volume=6&amp;publication_year=2007&amp;pages=138-146&amp;pmid=17237274&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib49"><span class="mixed-citation">Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:2139–2146.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2718422/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18390968" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+the+oral,+small-molecule+mitogen-activated+protein+kinase+kinase+1/2+inhibitor+AZD6244+(ARRY-142886)+in+patients+with+advanced+cancers&amp;author=AA+Adjei&amp;author=RB+Cohen&amp;author=W+Franklin&amp;author=C+Morris&amp;author=D+Wilson&amp;volume=26&amp;publication_year=2008&amp;pages=2139-2146&amp;pmid=18390968&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib50"><span class="mixed-citation">Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. <span><span class="ref-journal">JThorac Oncol. </span>2010;<span class="ref-vol">5</span>:1630–1636.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20802351" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JThorac+Oncol&amp;title=A+phase+II,+open-label,+randomized+study+to+assess+the+efficacy+and+safety+of+AZD6244+(ARRY-142886)+versus+pemetrexed+in+patients+with+non-small+cell+lung+cancer+who+have+failed+one+or+two+prior+chemotherapeutic+regimens&amp;author=JD+Hainsworth&amp;author=CL+Cebotaru&amp;author=V+Kanarev&amp;author=TE+Ciuleanu&amp;author=D+Damyanov&amp;volume=5&amp;publication_year=2010&amp;pages=1630-1636&amp;pmid=20802351&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib51"><span class="mixed-citation">Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. <span><span class="ref-journal">Invest New Drugs. </span>2011;<span class="ref-vol">25</span>:1021–1028.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20127139" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Invest+New+Drugs&amp;title=A+Phase+II,+open-label,+randomised+study+to+assess+the+efficacy+and+safety+of+the+MEK1/2+inhibitor+AZD6244+(ARRY-142886)+versus+capecitabine+monotherapy+in+patients+with+colorectal+cancer+who+have+failed+one+or+two+prior+chemotherapeutic+regimens&amp;author=J+Bennouna&amp;author=I+Lang&amp;author=M+Valladares-Ayerbes&amp;author=K+Boer&amp;author=A+Adenis&amp;volume=25&amp;publication_year=2011&amp;pages=1021-1028&amp;pmid=20127139&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib52"><span class="mixed-citation">O'Neil BH, Goff LW, Kauh JSW, Strosberg JR, Bekaii-Saab TS, Lee RM, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span>:2350–2356.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3107750/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21519015" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+II+study+of+the+mitogen-activated+protein+kinase+1/2+inhibitor+selumetinib+in+patients+with+advanced+hepatocellular+carcinoma&amp;author=BH+O'Neil&amp;author=LW+Goff&amp;author=JSW+Kauh&amp;author=JR+Strosberg&amp;author=TS+Bekaii-Saab&amp;volume=29&amp;publication_year=2011&amp;pages=2350-2356&amp;pmid=21519015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib53"><span class="mixed-citation">Goutopoulos A, Askew B, Bankston D, Clark A, Dhanabal M, Dong R, et al.AS703026: a novel allosteric MEK inhibitor. <em>In: 100th Annual Meeting of the American Association for Cancer Research</em> 2009; (Abstract [4776]).</span></li><li id="bib54"><span class="mixed-citation">Awada A, Houede N, Delord JP, Dubuisson M, Italiano A, Berge Y, et al.Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors. <em>In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics</em> 2010; (Abstract [374]).</span></li><li id="bib55"><span class="mixed-citation">Johnston S.XL518, a potent selective orally bioavailable MEK1 inhibitor, downregulates the RAS/RAF/MEK/ERK pathway <em>in vivo</em>, resulting in tumor growth inhibition and regression in pre-clinical models. <em>In: 20th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics</em> 2007; (Abstract [C209]).</span></li><li id="bib56"><span class="mixed-citation">Rosen L, LoRusso P, Wee W, Goldman J, Weise A, Colevas AD, et al.A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. <em>In: 102nd Annual Meeting of the American Association for Cancer Research</em> 2011; (Abstract [3611]).</span></li><li id="bib57"><span class="mixed-citation">Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. <span><span class="ref-journal">Cancer Res. </span>2009;<span class="ref-vol">69</span>:6839–6847.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19706763" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=RDEA119/BAY+869766:+A+potent,+selective,+allosteric+inhibitor+of+MEK1/2+for+the+treatment+of+cancer&amp;author=C+Iverson&amp;author=G+Larson&amp;author=C+Lai&amp;author=LT+Yeh&amp;author=C+Dadson&amp;volume=69&amp;publication_year=2009&amp;pages=6839-6847&amp;pmid=19706763&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib58"><span class="mixed-citation">Weekes C, Von Hoff DD, Adjei AA, Yeh LT, Leffingwell D, Sheedy B, et al.A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients. <em>In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics</em> 2010; (Abstract [109]).</span></li><li id="bib59"><span class="mixed-citation">Gilmartin AG, Kusnlerx AM, Sutton D, Moss KG, Thompson CS, Weber BL, et al.GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models. <em>In: 20th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics</em> 2008; (Abstract [567]).</span></li><li id="bib60"><span class="mixed-citation">Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained <em>in vivo</em> pathway inhibition. <span><span class="ref-journal">Clin Cancer Res. </span>2011;<span class="ref-vol">17</span>:989–1000.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21245089" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=GSK1120212+(JTP-74057)+is+an+inhibitor+of+MEK+activity+and+activation+with+favorable+pharmacokinetic+properties+for+sustained+in+vivo+pathway+inhibition&amp;author=AG+Gilmartin&amp;author=MR+Bleam&amp;author=A+Groy&amp;author=KG+Moss&amp;author=EA+Minthorn&amp;volume=17&amp;publication_year=2011&amp;pages=989-1000&amp;pmid=21245089&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib61"><span class="mixed-citation">Gordon MS, Infante JR, Messersmith LA, Vogelzang NJ, Cox D, DeMarini DJ, et al.The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: pharmacokinetic, pharmacodynamic, and clinical response relationship. <em>In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics</em> 2010; (Abstract [373]).</span></li><li id="bib62"><span class="mixed-citation">Borthakur G, Popplewell L, Kirschbaum MH, Foran JM, Kadia TM, Jabbour E, et al. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: evidence of activity in pts with RAS mutation [abstract] <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span> (suppl:abstr 6506.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I/II+trial+of+the+MEK1/2+inhibitor+GSK1120212+(GSK212)+in+patients+(pts)+with+relapsed/refractory+myeloid+malignancies:+evidence+of+activity+in+pts+with+RAS+mutation+[abstract]&amp;author=G+Borthakur&amp;author=L+Popplewell&amp;author=MH+Kirschbaum&amp;author=JM+Foran&amp;author=TM+Kadia&amp;volume=29&amp;publication_year=2011&amp;pages=abstr+6506&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib63"><span class="mixed-citation">Huynh H, Chow PKH, Soo KC. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. <span><span class="ref-journal">Mol Cancer Ther. </span>2007;<span class="ref-vol">6</span>:2468–2476.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17876044" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=AZD6244+and+doxorubicin+induce+growth+suppression+and+apoptosis+in+mouse+models+of+hepatocellular+carcinoma&amp;author=H+Huynh&amp;author=PKH+Chow&amp;author=KC+Soo&amp;volume=6&amp;publication_year=2007&amp;pages=2468-2476&amp;pmid=17876044&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib64"><span class="mixed-citation">Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. <span><span class="ref-journal">Clin Cancer Res. </span>2008;<span class="ref-vol">14</span>:230–239.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18172275" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=The+mitogen-activated+protein/extracellular+signal-regulated+kinase+kinase+inhibitor+AZD6244+(ARRY-142886)+induces+growth+arrest+in+melanoma+cells+and+tumor+regression+when+combined+with+docetaxel&amp;author=NK+Haass&amp;author=K+Sproesser&amp;author=TK+Nguyen&amp;author=R+Contractor&amp;author=CA+Medina&amp;volume=14&amp;publication_year=2008&amp;pages=230-239&amp;pmid=18172275&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib65"><span class="mixed-citation">Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. <span><span class="ref-journal">Apoptosis. </span>2009;<span class="ref-vol">14</span>:1108–1120.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19548087" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Apoptosis&amp;title=Inhibition+of+MEK+signaling+enhances+the+ability+of+cytarabine+to+induce+growth+arrest+and+apoptosis+of+acute+myelogenous+leukemia+cells&amp;author=C+Nishioka&amp;author=T+Ikezoe&amp;author=J+Yang&amp;author=A+Yokoyama&amp;volume=14&amp;publication_year=2009&amp;pages=1108-1120&amp;pmid=19548087&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib66"><span class="mixed-citation">McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EWT, Steelman LS, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. <span><span class="ref-journal">Leukemia. </span>2008;<span class="ref-vol">22</span>:2080–2090.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18685611" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Involvement+of+p53+and+Raf/MEK/ERK+pathways+in+hematopoietic+drug+resistance&amp;author=JA+McCubrey&amp;author=SL+Abrams&amp;author=G+Ligresti&amp;author=N+Misaghian&amp;author=EWT+Wong&amp;volume=22&amp;publication_year=2008&amp;pages=2080-2090&amp;pmid=18685611&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib67"><span class="mixed-citation">Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. <span><span class="ref-journal">Mol Pharmacol. </span>2001;<span class="ref-vol">60</span>:143–154.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11408609" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharmacol&amp;title=Sequence-dependent+potentiation+of+paclitaxel-mediated+apoptosis+in+human+leukemia+cells+by+inhibitors+of+the+mitogen-activated+protein+kinase+kinase/mitogen-activated+protein+kinase+pathway&amp;author=C+Yu&amp;author=S+Wang&amp;author=P+Dent&amp;author=S+Grant&amp;volume=60&amp;publication_year=2001&amp;pages=143-154&amp;pmid=11408609&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib68"><span class="mixed-citation">Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. <span><span class="ref-journal">Science Signaling. </span>2011;<span class="ref-vol">4</span>:166.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21447798" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science+Signaling&amp;title=Amplification+of+the+driving+oncogene,+KRAS+or+BRAF,+underpins+acquired+resistance+to+MEK1/2+inhibitors+in+colorectal+cancer+cells&amp;author=AS+Little&amp;author=K+Balmanno&amp;author=MJ+Sale&amp;author=S+Newman&amp;author=JR+Dry&amp;volume=4&amp;publication_year=2011&amp;pages=166&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib69"><span class="mixed-citation">Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. <span><span class="ref-journal">Science Signaling. </span>2010;<span class="ref-vol">3</span>:149.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3372405/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21098728" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science+Signaling&amp;title=BRAF+gene+amplification+can+promote+acquired+resistance+to+MEK+inhibitors+in+cancer+cells+harboring+the+BRAF+V600E+mutation&amp;author=RB+Corcoran&amp;author=D+Dias-Santagata&amp;author=K+Bergethon&amp;author=AJ+Iafrate&amp;author=J+Settleman&amp;volume=3&amp;publication_year=2010&amp;pages=149&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib70"><span class="mixed-citation">Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-Raf V600E mutation. <span><span class="ref-journal">Cancer Res. </span>2011;<span class="ref-vol">71</span>:5535–5545.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21705440" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Identification+of+the+MEK1(F129L)+activating+mutation+as+a+potential+mechanism+of+acquired+resistance+to+MEK+inhibition+in+human+cancers+carrying+the+B-Raf+V600E+mutation&amp;author=H+Wang&amp;author=S+Daouti&amp;author=WH+Li&amp;author=Y+Wen&amp;author=C+Rizzo&amp;volume=71&amp;publication_year=2011&amp;pages=5535-5545&amp;pmid=21705440&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib71"><span class="mixed-citation">Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:3329–3334.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2912210/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20472680" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Targeting+the+mitogen-activated+protein+kinase+pathway:+physiological+feedback+and+drug+response&amp;author=CA+Pratilas&amp;author=DB+Solit&amp;volume=16&amp;publication_year=2010&amp;pages=3329-3334&amp;pmid=20472680&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib72"><span class="mixed-citation">Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <span><span class="ref-journal">Aging (Milano) </span>2011;<span class="ref-vol">3</span>:192–222.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3091517/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21422497" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Aging+(Milano)&amp;title=Roles+of+the+Raf/MEK/ERK+and+PI3K/PTEN/Akt/mTOR+pathways+in+controlling+growth+and+sensitivity+to+therapy-implications+for+cancer+and+aging&amp;author=LS+Steelman&amp;author=WH+Chappell&amp;author=SL+Abrams&amp;author=RC+Kempf&amp;author=J+Long&amp;volume=3&amp;publication_year=2011&amp;pages=192-222&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib73"><span class="mixed-citation">Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. <span><span class="ref-journal">Int J Cancer. </span>2009;<span class="ref-vol">125</span>:2332–2341.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19637312" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Intrinsic+resistance+to+the+MEK1/2+inhibitor+AZD6244+(ARRY-142886)+is+associated+with+weak+ERK1/2+signalling+and/or+strong+PI3K+signalling+in+colorectal+cancer+cell+lines&amp;author=K+Balmanno&amp;author=SD+Chell&amp;author=AS+Gillings&amp;author=S+Hayat&amp;author=SJ+Cook&amp;volume=125&amp;publication_year=2009&amp;pages=2332-2341&amp;pmid=19637312&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib74"><span class="mixed-citation">Yoon YK, Kim HP, Han SW, Hur HS, Do YO, Im SA, et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <span><span class="ref-journal">Mol Cancer Ther. </span>2009;<span class="ref-vol">8</span>:2526–2536.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19755509" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Combination+of+EGFR+and+MEK1/2+inhibitor+shows+synergistic+effects+by+suppressing+EGFR/HER3-dependent+AKT+activation+in+human+gastric+cancer+cells&amp;author=YK+Yoon&amp;author=HP+Kim&amp;author=SW+Han&amp;author=HS+Hur&amp;author=YO+Do&amp;volume=8&amp;publication_year=2009&amp;pages=2526-2536&amp;pmid=19755509&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib75"><span class="mixed-citation">Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. <span><span class="ref-journal">Nat Med. </span>2008;<span class="ref-vol">14</span>:1351–1356.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2683415/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19029981" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Effective+use+of+PI3K+and+MEK+inhibitors+to+treat+mutant+Kras+G12D+and+PIK3CA+H1047R+murine+lung+cancers&amp;author=JA+Engelman&amp;author=L+Chen&amp;author=X+Tan&amp;author=K+Crosby&amp;author=AR+Guimaraes&amp;volume=14&amp;publication_year=2008&amp;pages=1351-1356&amp;pmid=19029981&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib76"><span class="mixed-citation">Bendell J, LoRusso P, Kwak E, Pandya S, Musib L, Jones C, et al.Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors. <em>In: 102nd Annual Meeting of the American Association for Cancer Research</em> 2011; (Abstract [LB-89]).</span></li><li id="bib77"><span class="mixed-citation">Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos KP, Smith DA, et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795) <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span> (suppl:abstr 3085.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I+dose-escalation+of+the+oral+MEK1/2+inhibitor+GSK1120212+(GSK212)+dosed+in+combination+with+the+oral+AKT+inhibitor+GSK2141795+(GSK795)&amp;author=R+Kurzrock&amp;author=A+Patnaik&amp;author=L+Rosenstein&amp;author=S+Fu&amp;author=KP+Papadopoulos&amp;volume=29&amp;publication_year=2011&amp;pages=abstr+3085&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib78"><span class="mixed-citation">Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. <span><span class="ref-journal">Mol Carcinog. </span>2010;<span class="ref-vol">49</span>:353–362.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20358631" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Carcinog&amp;title=KRAS+mutant+lung+cancer+cells+are+differentially+responsive+to+MEK+inhibitor+due+to+AKT+or+STAT3+activation:+implication+for+combinatorial+approach&amp;author=YK+Yoon&amp;author=HP+Kim&amp;author=SW+Han&amp;author=DY+Oh&amp;author=SA+Im&amp;volume=49&amp;publication_year=2010&amp;pages=353-362&amp;pmid=20358631&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib79"><span class="mixed-citation">Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. <span><span class="ref-journal">Cancer Res. </span>2011;<span class="ref-vol">71</span>:3658–3668.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3392199/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21444672" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=STAT3+mediates+resistance+to+MEK+inhibitor+through+microRNA+miR-17&amp;author=B+Dai&amp;author=J+Meng&amp;author=M+Peyton&amp;author=L+Girard&amp;author=WG+Bornmann&amp;volume=71&amp;publication_year=2011&amp;pages=3658-3668&amp;pmid=21444672&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib80"><span class="mixed-citation">Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. <span><span class="ref-journal">Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. </span>2009;<span class="ref-vol">23</span>:2222–2232.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3133628/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19741729" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia:+official+journal+of+the+Leukemia+Society+of+America,+Leukemia+Research+Fund,+UK&amp;title=The+use+of+novel+agents+in+the+treatment+of+relapsed+and+refractory+multiple+myeloma&amp;author=JP+Laubach&amp;author=A+Mahindra&amp;author=CS+Mitsiades&amp;author=RL+Schlossman&amp;author=NC+Munshi&amp;volume=23&amp;publication_year=2009&amp;pages=2222-2232&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib81"><span class="mixed-citation">Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:679–686.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3324254/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20385792" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Lenalidomide,+bortezomib,+and+dexamethasone+combination+therapy+in+patients+with+newly+diagnosed+multiple+myeloma&amp;author=PG+Richardson&amp;author=E+Weller&amp;author=S+Lonial&amp;author=AJ+Jakubowiak&amp;author=S+Jagannath&amp;volume=116&amp;publication_year=2010&amp;pages=679-686&amp;pmid=20385792&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib82"><span class="mixed-citation">Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <span><span class="ref-journal">The Lancet. </span>2010;<span class="ref-vol">376</span>:2075–2085.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21146205" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Lancet&amp;title=Bortezomib+with+thalidomide+plus+dexamethasone+compared+with+thalidomide+plus+dexamethasone+as+induction+therapy+before,+and+consolidation+therapy+after,+double+autologous+stem-cell+transplantation+in+newly+diagnosed+multiple+myeloma:+a+randomised+phase+3+study&amp;author=M+Cavo&amp;author=P+Tacchetti&amp;author=F+Patriarca&amp;author=MT+Petrucci&amp;author=L+Pantani&amp;volume=376&amp;publication_year=2010&amp;pages=2075-2085&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib83"><span class="mixed-citation">Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. <span><span class="ref-journal">Leukemia. </span>2009;<span class="ref-vol">23</span>:10–24.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3418600/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18843284" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Bone+marrow+microenvironment+and+the+identification+of+new+targets+for+myeloma+therapy&amp;author=K+Podar&amp;author=D+Chauhan&amp;author=KC+Anderson&amp;volume=23&amp;publication_year=2009&amp;pages=10-24&amp;pmid=18843284&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib84"><span class="mixed-citation">Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:1656–1663.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1975848/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17510321" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Targeting+MEK+induces+myeloma-cell+cytotoxicity+and+inhibits+osteoclastogenesis&amp;author=YT+Tai&amp;author=M+Fulciniti&amp;author=T+Hideshima&amp;author=W+Song&amp;author=M+Leiba&amp;volume=110&amp;publication_year=2007&amp;pages=1656-1663&amp;pmid=17510321&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib85"><span class="mixed-citation">Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. <span><span class="ref-journal">Br J Haematol. </span>2007;<span class="ref-vol">139</span>:55–63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17854307" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Haematol&amp;title=Targeting+MEK1/2+blocks+osteoclast+differentiation,+function+and+cytokine+secretion+in+multiple+myeloma&amp;author=I+Breitkreutz&amp;author=MS+Raab&amp;author=S+Vallet&amp;author=T+Hideshima&amp;author=N+Raje&amp;volume=139&amp;publication_year=2007&amp;pages=55-63&amp;pmid=17854307&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib86"><span class="mixed-citation">Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity <em>in vitro</em> and <em>in vivo</em>. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">149</span>:537–549.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3418597/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20331454" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Haematol&amp;title=Blockade+of+the+MEK/ERK+signalling+cascade+by+AS703026,+a+novel+selective+MEK1/2+inhibitor,+induces+pleiotropic+anti-myeloma+activity+in+vitro+and+in+vivo&amp;author=K+Kim&amp;author=SY+Kong&amp;author=M+Fulciniti&amp;author=X+Li&amp;author=W+Song&amp;volume=149&amp;publication_year=2010&amp;pages=537-549&amp;pmid=20331454&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib87"><span class="mixed-citation">Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:4055–4062.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12531799" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Molecular+sequelae+of+histone+deacetylase+inhibition+in+human+malignant+B+cells&amp;author=N+Mitsiades&amp;author=CS+Mitsiades&amp;author=PG+Richardson&amp;author=C+McMullan&amp;author=V+Poulaki&amp;volume=101&amp;publication_year=2003&amp;pages=4055-4062&amp;pmid=12531799&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib88"><span class="mixed-citation">Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2006;<span class="ref-vol">5</span>:769–784.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16955068" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Discov&amp;title=Anticancer+activities+of+histone+deacetylase+inhibitors&amp;author=JE+Bolden&amp;author=MJ+Peart&amp;author=RW+Johnstone&amp;volume=5&amp;publication_year=2006&amp;pages=769-784&amp;pmid=16955068&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib89"><span class="mixed-citation">Wolf JL, Siegel D, Jeffrey M, Lonial S, Goldschmidt H, Schmitt S, et al.A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. <em>In: 50th ASH Annual Meeting and Exposition</em> 2008; (Abstract [2774]).</span></li><li id="bib90"><span class="mixed-citation">Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. <span><span class="ref-journal">Cancer. </span>2011;<span class="ref-vol">117</span>:336–342.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3010462/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20862746" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Phase+2+trial+of+the+histone+deacetylase+inhibitor+romidepsin+for+the+treatment+of+refractory+multiple+myeloma&amp;author=R+Niesvizky&amp;author=S+Ely&amp;author=T+Mark&amp;author=S+Aggarwal&amp;author=JL+Gabrilove&amp;volume=117&amp;publication_year=2011&amp;pages=336-342&amp;pmid=20862746&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib91"><span class="mixed-citation">Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy <em>in vitro</em> and <em>in vivo</em>. <span><span class="ref-journal">Leuk Res. </span>2011;<span class="ref-vol">35</span>:373–379.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20650529" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leuk+Res&amp;title=The+histone+deacetylase+inhibitor+LBH589+enhances+the+anti-myeloma+effects+of+chemotherapy+in+vitro+and+in+vivo&amp;author=E+Sanchez&amp;author=J+Shen&amp;author=J+Steinberg&amp;author=M+Li&amp;author=C+Wang&amp;volume=35&amp;publication_year=2011&amp;pages=373-379&amp;pmid=20650529&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib92"><span class="mixed-citation">Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fern&#x000e1;ndez-L&#x000e1;zaro D, et al. <em>In vitro</em> and <em>in vivo</em> rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:794–803.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2864386/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19951978" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=In+vitro+and+in+vivo+rationale+for+the+triple+combination+of+panobinostat+(LBH589)+and+dexamethasone+with+either+bortezomib+or+lenalidomide+in+multiple+myeloma&amp;author=EM+Ocio&amp;author=D+Vilanova&amp;author=P+Atadja&amp;author=P+Maiso&amp;author=E+Crusoe&amp;volume=95&amp;publication_year=2010&amp;pages=794-803&amp;pmid=19951978&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib93"><span class="mixed-citation">Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL&#x0002b; human leukemia cells. <span><span class="ref-journal">Leukemia. </span>2005;<span class="ref-vol">19</span>:1579–1589.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16015388" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Synergistic+interactions+between+MEK1/2+and+histone+deacetylase+inhibitors+in+BCR/ABL&#x0002b;+human+leukemia+cells&amp;author=C+Yu&amp;author=G+Dasmahapatra&amp;author=P+Dent&amp;author=S+Grant&amp;volume=19&amp;publication_year=2005&amp;pages=1579-1589&amp;pmid=16015388&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib94"><span class="mixed-citation">Ozaki Ki, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S, et al. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2010;<span class="ref-vol">391</span>:1610–1615.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20026060" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Blockade+of+the+ERK+or+PI3K-Akt+signaling+pathway+enhances+the+cytotoxicity+of+histone+deacetylase+inhibitors+in+tumor+cells+resistant+to+gefitinib+or+imatinib&amp;author=Ki+Ozaki&amp;author=M+Kosugi&amp;author=N+Baba&amp;author=K+Fujio&amp;author=T+Sakamoto&amp;volume=391&amp;publication_year=2010&amp;pages=1610-1615&amp;pmid=20026060&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib95"><span class="mixed-citation">Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. <span><span class="ref-journal">Current Opinion in Drug Discovery and Development. </span>2006;<span class="ref-vol">9</span>:483–495.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16889231" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+Opinion+in+Drug+Discovery+and+Development&amp;title=Targeting+Hsp90+for+the+treatment+of+cancer&amp;author=MJ+Drysdale&amp;author=PA+Brough&amp;author=A+Massey&amp;author=MR+Jensen&amp;author=J+Schoepfer&amp;volume=9&amp;publication_year=2006&amp;pages=483-495&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib96"><span class="mixed-citation">Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, et al. Antimyeloma activity of heat shock protein-90 inhibition. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:1092–1100.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1895907/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16234364" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Antimyeloma+activity+of+heat+shock+protein-90+inhibition&amp;author=CS+Mitsiades&amp;author=NS+Mitsiades&amp;author=CJ+McMullan&amp;author=V+Poulaki&amp;author=AL+Kung&amp;volume=107&amp;publication_year=2006&amp;pages=1092-1100&amp;pmid=16234364&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib97"><span class="mixed-citation">Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. <span><span class="ref-journal">Mol Cancer Ther. </span>2011;<span class="ref-vol">10</span>:1909–1917.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21859842" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Targeting+HSP+90+induces+apoptosis+and+inhibits+critical+survival+and+proliferation+pathways+in+multiple+myeloma&amp;author=T+Khong&amp;author=A+Spencer&amp;volume=10&amp;publication_year=2011&amp;pages=1909-1917&amp;pmid=21859842&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib98"><span class="mixed-citation">Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) <span><span class="ref-journal">Cancer Res. </span>2010;<span class="ref-vol">70</span>:2264–2273.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3166660/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20215513" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Transcriptional+pathway+signatures+predict+MEK+addiction+and+response+to+selumetinib+(AZD6244)&amp;author=JR+Dry&amp;author=S+Pavey&amp;author=CA+Pratilas&amp;author=C+Harbron&amp;author=S+Runswick&amp;volume=70&amp;publication_year=2010&amp;pages=2264-2273&amp;pmid=20215513&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib99"><span class="mixed-citation">Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, et al. Amechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2396–2404.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3062408/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21163924" ref="reftype=pubmed&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Amechanistic+rationale+for+MEK+inhibitor+therapy+in+myeloma+based+on+blockade+of+MAF+oncogene+expression&amp;author=CM+Annunziata&amp;author=L+Hernandez&amp;author=RE+Davis&amp;author=A+Zingone&amp;author=L+Lamy&amp;volume=117&amp;publication_year=2011&amp;pages=2396-2404&amp;pmid=21163924&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3615214&amp;issue-id=221395&amp;journal-id=1694&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib100"><span class="mixed-citation">Zingone A, Korde N, Chen J, Xi L, Raffled M, Holkova B, et al.Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study. <em>In: 53rd ASH Annual Meeting and Exposition</em> 2011; (Abstract [306]).</span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Blood Cancer Journal</span> are provided here courtesy of <strong>Nature Publishing Group</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  


    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pubreader-link other_item"><a href="/pmc/articles/PMC3615214/?report=reader" class="sidefm-pmclink">PubReader</a></li>
<li class="pdf-link other_item"><a href="/pmc/articles/PMC3615214/pdf/bcj20131a.pdf" class="int-view">PDF (340K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/?format=citation&id=3615214" data-citation-style="nlm"
                        data-download-format-method="get"
                        data-download-format-link="https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/?format=medline&id=3615214&download=true"><span class="button-label">Cite</span></button>
            </li>
            <li>
                
                    




    <div class="favorites-button-container"
         id="pmc-favorites-button"
         data-toggle-favorites-enabled="false"
         data-add-to-favorites-url-hash="#add-to-favorites"
         data-in-favorites="false"
         data-toggle-url="https://www.ncbi.nlm.nih.gov/pmc/toggle-favorites-collection/PMC3615214/"
         data-collections-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"
         data-remove-from-favorites-text="Remove from Favorites collection"
         data-add-to-favorites-text="Add to Favorites collection"
         data-display-title-attr="Favorites">
        
            <a href="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A//www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/%23add-to-favorites"
               class="usa-button favorites-button favorites-button-empty favorites-button-link"
               id="pmc-favorites-button-link"
               
               aria-label="Add to Favorites collection"
               >
                Favorites
            </a>
        
    </div>


                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3615214%2F&amp;text=MEK%20inhibitors%20as%20a%20chemotherapeutic%20intervention%20in%20multiple%20myeloma" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3615214%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615214/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    
        <section>
            <h6>RESOURCES</h6>
            <ul class="pmc-sidebar__pubmed_links">
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&amp;from_uid=23524590">Similar articles in PubMed</a></li>
            </ul>
        </section>
    


    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.54110350c77632754ed7.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.6cf6664daa2b.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.616810c7e3ecd39f8cb2.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC3615214/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
        
      
            <a class="custom-feedback-button custom-feedback-button--base"  href="https://support.nlm.nih.gov/support/create-case/?from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3615214%2F"
         ref="linksrc=feedback_btn" rel="noopener noreferrer nofollow" target="_blank">Feedback</a>
      
  

</body>
</html>
